AD_____

Award Number: W81XWH-11-2-0232

TITLE: Extension of a Computer Assisted Decision Support (CADS) Study to Improve Outcomes in Patients with Type 2 DM Treated by Primary Cary Providers (short title, CADS-X)

PRINCIPAL INVESTIGATOR: Dr. Robert Vigersky

CONTRACTING ORGANIZATION: The Geneva Foundation

Tacoma, WA 98402

REPORT DATE: October 2012

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

			Form Approved		
	EPORT DOC		OMB No. 0704-0188		
					earching existing data sources, gathering and maintaining the s collection of information, including suggestions for reducing
					efferson Davis Highway, Suite 1204, Arlington, VA 22202- with a collection of information if it does not display a currently
		R FORM TO THE ABOVE ADD			
1. REPORT DATE		2. REPORT TYPE		-	DATES COVERED
October 2012		Annual			0September2011-29September2012
4. TITLE AND SUBTIT					a. CONTRACT NUMBER
	•	••••	DS) Study to Improv		
Outcomes in Patie	nts with Type 2 DN	I Treated by Primar	y Cary Providers		b. GRANT NUMBER
				V	/81XWH-11-2-0232
				50	C. PROGRAM ELEMENT NUMBER
6. AUTHOR(S)				50	d. PROJECT NUMBER
Dr. Robert Vigersk	у			50	e. TASK NUMBER
robert.vigersky@u	s.army.mil			51	. WORK UNIT NUMBER
7. PERFORMING ORG	ANIZATION NAME(S)	AND ADDRESS(ES)			PERFORMING ORGANIZATION REPORT
				N	UMBER
The Geneva Found	dation, Tacoma, W	/A 98402			
9. SPONSORING / MO	NITORING AGENCY N	AME(S) AND ADDRES	S(ES)	10	D. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical					
Fort Detrick, Maryl	and 21702-5012				
				1	1. SPONSOR/MONITOR'S REPORT
					NUMBER(S)
12. DISTRIBUTION / A	VAII ABII ITY STATEN	IFNT			
Approved for Publi	-				
13. SUPPLEMENTAR	NOTES				
13. SUFFLEMENTAR	NOTES				
14. ABSTRACT	this proposal is to t	aat tha lange tarma a	linical offects of a C		ated Decision Support (CADS)
					sted Decision Support (CADS)
					reover, the aims are to compare
					ADS system for differing durations.
					ntinuously or up to a certain threshold
					year funded through United States
					2-0196, and is currently ongoing) for a
					study including the Army (Walter
Reed Health Care	System or WHCS)	, the Air Force (Wilf	ord Hall Medical Ce	enter or WHM	C), and the University of Hawaii (UH).
					Iready funded one. A detailed,
		and hardware elem	ents of this study ar	e included in	reports for the original CADS study
and available upor	request.				
15. SUBJECT TERMS	none provided				
	1				
16. SECURITY CLASS			17. LIMITATION	18. NUMBER	19a. NAME OF RESPONSIBLE PERSON
10. SECONITI CLASS	I IOATION OF.		OF ABSTRACT	OF PAGES	USAMRMC
	b. ABSTRACT	c. THIS PAGE			
a. REPORT U		U U	UU	74	19b. TELEPHONE NUMBER (include area code)
U	0				,
				1	

Table of Contents

<u>Page</u>

Introduction	4
Body	6
Key Research Accomplishments	8
Reportable Outcomes	11
Conclusion	11
References	12
Appendices	15

INTRODUCTION

Diabetes mellitus (DM) affects nearly 26 million people in the United States and is associated with devastating complications in both personal and financial terms. Diabetes is the leading cause of blindness, non-traumatic amputations, and renal failure in adults and reduces life expectancy by 5-10 years. The direct (\$116 billion) and indirect (\$68 billion) costs of DM care have dramatically increased along with the epidemic increase in the number of those with DM over the past 10 years. The cost of medical care per capita is approximately \$10,000 per year compared with \$2,700 per year for those without DM. The vast majority of these costs are related to hospitalizations resulting from the chronic complications of DM, with only about 15% of the costs attributable to professional visits and pharmaceuticals.

The Diabetes Control and Complications Trial (DCCT), the United Kingdom Prospective Diabetes Study (UKPDS), and the "Kumamoto" study conclusively proved that improved glycemic control is important in reducing microvascular complications (1-3). Together, these studies showed that for every 1% decrease in A1C, there is a 25% decrease in microvascular complications. Based on these studies, the American Diabetes Association (ADA) recommends that the goal for A1C should be below 7% (normal = 4 - 6.1%) (4), and the American Association of Clinical Endocrinologists (AACE) recommends that it should be below 6.5%, corresponding to average blood glucose (BG) values of 150 and 135 mg/dL, respectively, [normal = 70 - 126 mg/dl] (5). Furthermore, years of improved glycemic control appear to have a legacy effect and not only reduce the future rate of microvascular complications but also decrease the incidence of macrovascular complications in both Type 1 and Type 2 diabetes (6-7).

Hypertension is one of the most common co-morbidities associated with DM and substantially contributes to the macrovascular disease that occurs in up to 80% of patients with DM (14). Several large randomized clinical trials (RCTs), including the UKPDS, demonstrated that, independent of the effects of glycemic control, improving blood pressure (BP) control significantly reduced macrovascular complications and cardiovascular-related deaths (14-17). Similarly, the UKPDS showed a 13% reduction in microvascular complications for every 10 mmHg reduction in systolic pressure (18). This finding was confirmed and extended to DM patients who were "normotensive" (19). Gaede et al. showed the marked benefit of aggressive blood pressure, lipid, and blood glucose management achieved through multifactorial intervention (20). There also appears to be a legacy effect of blood pressure control in Type 2 diabetes as recently shown by Holman et al. (21).

Despite the well-documented benefits of glycemic and BP control, these are still sub-optimal in most patients. Although there is a trend toward improved glycemic control, the latest (2004) National Health and Nutrition Examination Survey (NHANES) data demonstrated that 42.3% of patients with DM have A1Cs over 7% (22). The military healthcare system (MHS) - where there is no cost to the patient for care and testing supplies - has similar results with hemoglobin A1C's over 7% in 42% of all patients with diabetes, and over 9% in 23.3% of all patients with diabetes. The data from the Walter Reed Health Care System (WRHCS) is similar, with 51% of all patients with diabetes having an A1C above 7% as of December, 2009. Furthermore, BP control in our patients is similar to the national average, with 62% of our patients having either systolic over 140 mmHg and/or diastolic over 90 mmHg under current treatment. Recommended levels to reduce the risk of cardiovascular mortality and morbidity are less than 130/80 mm/Hg.

Reasons for Sub-optimal Achievement of Diabetes Control

The reasons why more patients do not reach appropriate goals for glycemic control are multiple and complex. First, due to an insufficient number of Endocrinologists and Certified Diabetes Educators in both military and civilian health care settings (23), the vast majority of patients with DM are managed by primary care providers (PCPs), including family practitioners, nurse generalists, nurse practitioners, and physicians' assistants, who are not necessarily equipped with the latest information and tools to provide optimum care, nor have the time required to evaluate relevant data necessary to do so. The patient may bring his/her handwritten logbook and/or meter to the clinic, where the data must be reviewed manually or the patient will bring his/her memory-equipped meter to the clinic, where it may be uploaded to the provider's computer and analyzed. Manual review of the records precludes any statistical and graphical analysis of the data and often limits the provider's ability to recognize patterns and trends. Moreover, this approach is a time-consuming and an inefficient use of both the provider's and patient's time. Uploading of the glucose data provides the requisite statistical and graphical analysis. However, all the major glucose meter manufacturers have their own proprietary software – none of which are integrated into the electronic medical record (EMR) - and each of the meters has its own unique connecting cable. Thus, the multiplicity of non-integrated programs and connecting cables prevent the provider from efficiently reviewing BG data and thus creates a significant barrier to using this technology.

Second, the introduction of new oral and parenteral agents has exponentially increased the complexity of the management of T2DM in the last 10-15 years. Prior to the introduction of metformin in 1995, the only available class of oral agents was sulfonylureas. Now there are thirteen classes of oral medications, insulins, and non-insulin injectables. Recombinant human insulin and analog insulins have come into common use and the long-acting insulin analogs (insulin glargine and Detemir) have been incorporated into many regimens for Type 2 diabetes, either alone or in combination with oral agents. The enormous number of possible combinations of therapeutic agents makes it difficult for physicians to be familiar with all available approaches. Making matters more complex is that for each class there may be several options, e.g. for insulin

secretagogues one can choose sulfonylureas like glipizide, glipizide-XL, or glyburide or a meglitinide such as nateglinide or repaglinide.

Third, self-monitoring of blood glucose (SMBG) on the part of the patient is an essential tool in achieving improved glycemic control. Several studies have shown that improved glycemic control is cost effective in both Type 1 and Type 2 DM (T1DM and T2DM) despite the increase in cost of supplies, a greater number of clinic visits, and more pharmaceuticals used. Yet, many patients do not monitor as recommended, in part because of the barriers noted above (e.g., they perceive that their providers cannot or do not review the SMBG results), a lack of understanding of how to use their glucose data to improve their glycemic control, as well as social and personal barriers.

The Case for Systematic, Rigorous Examination of a Computer Assisted Decision Support System for Diabetes Management

Although many studies have demonstrated the potential advantages of telemedicine, web-based, and/or web-assisted DM management, most have used the web for patient education, performance monitoring, risk stratification, and case management by nurses (24-26). Only a few studies have shown that using the web and/or e-mail improves glycemic control (27-29) or can reduce the number of clinic visits (30) while others have not been able to show such an effect (31-32).

Computer-assisted algorithms to provide decision support for interpretation of the glucose profile have been previously developed and published by the collaborators on this project as well as others (33-36). We and our colleague (Berger) have previously developed methods to automatically select regimens and doses of insulin for patients with T1DM (37). Lehmann has adopted and slightly modified the models of Rodbard and Bergman, and used it to develop "AIDA" – http://www.2aida.org – a program intended for education of health care providers and patients (38). This has not been employed therapeutically and no controlled trials have been performed.

There are only a few studies investigating decision support in the management of diabetes. Holman (36) and Chiarelli (39) reported that portable decision support devices used by patients with T1DM resulted in improved glycemic control. A webbased decision support system (DSS) improved compliance with generally recognized process measures of DM care (e.g. the number of A1C and low density lipoprotein [LDL] tests obtained) but did not improve the actual A1C level (40). Cleveringa et al. were unable to show that a DSS used by a practical nurse improved A1C in T2DM although it did improve cardiovascular risk factors (41). Recently, the IDEATel consortium study showed that a telemedicine application improved A1C, BP and lipids in an older, ethnically diverse and underserved population (42). Salzsieder and colleagues used their Diabetiva® program to apply continuous glucose monitoring (CGM) data to a DSS to improve A1C (43). Decision support systems that have been used in blood pressure management show conflicting results (44-45).

Building on our prior experience in developing methods to select regimens and doses of insulin for patients with T1DM, we developed a CADS system for management of T2DM by PCPs to overcome many of the aforementioned barriers to the appropriate management of T2DM. The key feature of CADS is that it simplifies the work of the PCP by automatically integrating the essential factors necessary to make a recommendation for management - the patient's SMBG data from their uploads, current and previous medication, and current relevant laboratory data – and then making a recommendation based on established consensus algorithms (47).

BODY

The use of a computer assisted decision support (CADS) system has been described in detail in the quarterly, annual, and final reports that have been submitted. The goal of the first study (Year 1 or Months 1-12) was to determine whether or not the use of CADS by PCPs, i.e. Internists, Family Practitioners, Nurse Practitioners, and Physician's Assistants, can improve glycemic and other outcomes in patients with poorly controlled T2DM over one year. The theoretic construct for establishing the hypotheses is that non-endocrinologist providers have neither the time nor expertise to address critical issues of management for patients with T2DM and that a CADS system will help them do so. Additionally, a CADS system will, because it saves time in the management of glycemic-related outcomes, permit providers to give more attention to management of the important co-morbidities of T2DM. Finally, a patient with improved glycemic control and comorbidities will be more satisfied with their overall treatment.

This study, entitled "Extension of a Computer Assisted Decision Support (CADS-X) Study to Improve Outcomes in Patients with Type 2 DM Treated by Primary Care Providers" (CADS-X), was designed with two primary aims: (1) to provide those providers who were not assigned to the CADS arm in the initial study an opportunity to "cross-over" to CADS in a subsequent year provided that: a) CADS is shown to produce statistically significant improvements in A1C or other response variables (fasting plasma glucose {FPG}, post-prandial plasma glucose {PPG}, post prandial excursions, rate of hypoglycemia) and b) funding is available for continuation of the trial; and (2) to determine the legacy effect of CADS by providing primary care providers (PCPs) and their patients who were initially randomized to CADS an opportunity to use CADS for an additional year for a total of 2 years.

Significant challenges in the approval and implementation of the original study, "The Use of a Computer-Assisted Decision Support (CADS) System to Improve Outcomes in Patients with Type 2 Diabetes Who Are Treated by Primary Care Providers" (the CADS study), have delayed our ability to implement the extension study. The following provides a brief overview of the original study and the challenges that have prevented us from completing the first study.

The purpose of the original study, CADS, was to test the safety and efficacy of a computer assisted decision support (CADS) system in a multi-site, ethnically and geographically diverse study in a 12-month, open, prospective, clusterrandomized, controlled clinical trial. Specific aims included: (1) monitor the impact of the intervention on a) measures of glycemic control, b) the number of diabetes—related hospitalizations and emergency room visits, c) the control of comorbidities, hyperlipidemia and hypertension, d) the number of clinic visits, and e) the change in the patients' quality of life as a result of the intervention; and (2) evaluate the PCPs' and patients' satisfaction with the technology. The progress of the CADS study as well as the challenges to the achievement of our specific aims has been described in detail in quarterly and annual reports submitted for the original study.

The following summarizes the challenges and our solutions to date.

- 1. Institutional Review Board (IRB) approvals for the three participating institutions, Walter Reed Army Medical Center (WRAMC), Wilford Hall Medical Center (WHMC), and the University of Hawaii (UH) School of Medicine.
 - a. The protocol was submitted to the WRAMC IRB in December 2009. It was approved in March 2011.
 - b. The protocol was submitted to the WHMC in February 2010. The investigators received final approval to begin the study in October 2011.
- 2. The adverse impact of the Base Realignment and Closure (BRAC) in August 2011 and on several factors relating to IT and provider and patient re-assignment prior to August 2011:
 - a. The Information Assurance, Management, and Technology Departments at both Walter Reed National Military Medical Center (WRNMMC), formerly WRAMC, and Wilford Hall Ambulatory Surgery Center (WHASC), formerly WHMC.
 - i. The Comprehensive Diabetes Management Program (CDMP), a web-based chronic disease management program was designed to exchange relevant medical information with the Integrated Clinical Data Base (ICDB), the electronic medical record (EMR) for patients being treated at MTFs throughout the U.S. ICDB was disabled at WRAMC when AHLTA was introduced. Through much effort and two AAMTI grants, a bi-directional test link was developed between AHLTA and CDMP at WRAMC.
 - ii. It was then determined that CDMP and CADS must complete the DoD Information Assurance Certification and Accreditation Process (DIACAP) before they could be operationalized.
 - iii. WRNNMC began the DIACAP approximately 2 years ago. CDMP received DIACAP approval at WHMC, but the addition of CADS has required additional DIACAP certification.
 - iv. Delay of DIACAP certification has impacted the study in two major ways:
 - 1. There is no exchange of relevant patient information between the existing EMRs at WRNMMC and WHASC.
 - 2. Providers randomized to CADS and working at WRNMMC and WHASC are unable to access the program from their work computers.

- v. The following strategy will be utilized as a temporary strategy until CDMP/CADS has been DIACAP certified:
 - 1. The Project Officers (POs) at WRNMMC and WHASC will manually load into CDMP the information from the patient's EMR that is necessary to correctly run the CADS analysis. This information includes relevant laboratory values, current and past medications, and co-morbid or co-existing diagnoses.
 - 2. The PO and the provider will determine the patient's target A1C level which the PO will enter into the CADS program.
 - 3. Once the patients have uploaded their de-identified glucose data into a passwordprotected server, the Project Officers at WRNMMC and WHASC will run the data through the CADS analysis and provide recommendations via email to the subjects' providers.
 - 4. The providers will select one of the recommendations which the PO will then select in the program.
 - 5. If the provider does not choose to follow any of the recommendations the PO will ask him/her for a reason and document the reason given.
- b. The re-allocation of both providers and patients originally at WRAMC to either Fort Belvoir Community Hospital (FBCH) or Walter Reed National Military Medical Center (WRNMMC) further complicated enrollment for three reasons:
 - i. Providers did not necessarily retain their same panel of patients.
 - ii. There was a significant delay in recruiting from WRNMMC, FBCH, and KACC as both providers and patients became accustomed to new locations and, often, new rules and policies.
 - iii. We were advised in March 2012 that FBCH and KACC needed site specific addenda (SSAs) in order to participate in the study. Since we were submitting other addenda at the time, we were advised by the WRNNMC IRB to not submit the SSAs until the other addenda were submitted.
 - 1. SSAs for both sites were submitted in July 2012.
 - 2. Approval to begin recruitment at KACC in was received November 2012
 - 3. Approval to resume recruitment at FBCH is pending.
- 3. The most recent challenge to the research being conducted at WRNMMC and WHASC has to do with the method patients will use to upload their glucometers in order to run the CADS analysis.
 - a. *Metrikus, the original device developed by Numera, has been upgraded and is now called MetriLink.*
 - b. The negotiation of the contract between Numera and the Geneva Foundation was conducted independent of the research staff.
 - c. The research staff was not informed that, with few exceptions, the MetriLink requires analog, landline telephones in order to work.
 - d. When the protocol was being developed, the only information given to the researchers was that the device required a landline telephone in order to work.
 - e. This has presented a huge problem since most of the patients have carriers that combine internet, digital telephone, and cable TV as one package. Options:
 - i. Use of MyGlucoHealth, the cell phone compatible meter being used in HI is not an option because it was not budgeted, it is not on the Core Formulary at either WRNMMC or WHASC, and it would involve additional personnel costs as it would be distributed by the research pharmacy.
 - ii. There has been some success with clients using Comcast, but it is not guaranteed.
 - iii. There is a web-based connection that can be used with the purchase of a cable. The instructions are somewhat complex and thus add another level of complexity, and may require the patients to purchase them.
- 4. Recruitment efforts at UH have been hampered by providers who withdrew interest or were no longer practicing once the study began, and by the need to find additional providers in the clinics that have been approved to participate.
- 5. Recruitment efforts at all sites have been hindered by the sample size and A1C eligibility range. Efforts to address these factors are described in Research Accomplishments.

KEY RESEARCH ACCOMPLISHMENTS

Enrollment during Period of Performance:

WRNMMC: 11/18 providers; 18/234 patients. Providers need 13 patients for randomization. One provider has 10 patients who have been consented with 2 pending consent. Per protocol, once 13 patients per provider, provider and patient will be randomized to the intervention (CADS) or usual care.

WHASC: 7/18 providers; 17/234 patients. WHASC IRB required new consent forms for both providers and patients as a result of a recent amendment that reduced number of A1Cs within target range for eligibility from 2 to 1, increased number of providers and reduced number of patients per provider. The Project Officer at WHASC was required to re-consent providers and patients who had been previously consented. This requirement prompted another delay in recruitment.

UH: 5/6 providers; 2/78 patients.

An amendment identifying 2 changes designed to reduce barriers to enrollment was submitted and approved by all institutions' IRBs during the PoP:

- 1. Change in A1C requirement: We have determined that requiring 2 A1Cs does not add any scientific value to the study and may be a deterrent to enrolling patients.
- Change in sample size: Number of patients per provider was decreased from 19-13 at all three research sites and number of providers was increased from 12 to 18 at WRNMMC and WHASC. The number of providers at UH remained the same.

The new sample size estimate was generated as follows and is included in the revised protocol. First, we calculated the sample size that would be needed to test our primary hypothesis regarding glycemic control (defined as change in A1C) without yet accounting for the clustering effect. The sample size needed is based on achieving a decrease in A1C of 1.0% (between subject SD = 1.5%) in the CADS "Intervention" group and 0.5% (between subject SD = 1.7%) in the "Usual Care" group. These estimates, regarding the average amount of decline in A1C for the two groups and the standard deviation, are based on our prior research of intervention with continuous glucose monitoring in a group of patients with poorly controlled T2DM (presented at the Annual Meeting of the Endocrine Society, June 11, 2009 and separately at a meeting of the Diabetes Technology Society November 2009). (54, 55) Furthermore, we assumed an alpha of 0.05 and power of 0.80, with a 1:1 ratio in study groups. Given these parameters, we expect that one would need to recruit at least 324 patients (162 patients per group). The effect sizes were selected as the minimal changes likely to have clinical significance and therefore be able to warrant adoption by primary care providers.

Second, we 'corrected' the sample size estimate by taking into account the clustering effect. Based on previous research, we assumed that the intra-class correlation coefficient (ρ , rho) would be about 0.03. (54) For this 'correction', we further assumed that we would need a minimum of 10 patients per cluster, to allow each provider to have sufficient opportunity to work with CADS (n = 10 patients times 3 consultations with CADS [at 3, 6, and 9 months] = 30 consultations on average, with some getting more and some getting less). These assumptions generated an estimate for the number of clusters/providers we would need, which was 42. We will distribute the number of providers as follows to achieve 42: 18 clusters at the WRNMMC, 18 clusters at the WHMC, and 6 clusters at the UH.

Given these assumptions and constraints, we estimated that we need a minimum of 412 patients (206 per group) total, distributed among the providers, before taking attrition into account.

Third, we considered the effect of attrition over the course of 1 year. For this consideration, we assumed two types of attrition could occur – patient attrition and provider attrition. Provider attrition would result in the loss of both provider and his/her patients. For both types of attrition, we assumed rates of 15%. Thus, to adjust for the possibility of patient and provider attrition, we estimated that we need to recruit 546 patients across 42 clusters. On average, each provider will work with about 13 patients.

Bi-monthly Conference Calls

Bi-monthly conference calls are held to assess screening and recruitment activity, identify problems, and discuss solutions. Recruitment has been one of the most difficult aspects of this study. Our attempts to facilitate enrollment resulted in the amendment that reduced the number of A1C levels between 7 and 11% from 2 to 1 in the previous 6 months, and to change our sample size. Changing the sample size was predicated on our ability to enroll providers fairly easily. Thus, increasing the number of providers allowed us to decrease the number of patients required to test our primary hypothesis regarding glycemic control (defined as change in A1C). The elimination of one of the two A1C within the specified range required for study entry did not change the value of the study.

Other efforts to increase enrollment include face-to-face meetings between the research staff at each site and providers, email reminders to consented providers to inform site research staff of potential patients, and database searches.

CDMP and CADS Maintenance and Enhancements

Further delays in the DIACAP approval process at both WRNMMC and WHASC have been explained in the CADS 1st and 2nd quarterly reports and will not be repeated in this report. The DIACAP process is cited briefly in the section under Task 1.

Task 1

In support of the CADS research protocol, Estenda Solutions, Inc. will integrate CADS into each site's electronic medical record (EMR) as necessary, maintain the CADS/CDMP systems and the links with the site EMR, ensure that links with iMetrikus are continuously functional, provide secure storage of the data, and re-program and test the algorithms as deemed necessary by the PI. The CDMP, CADS and iMetrikus services are fully operating and available to research staff. Estenda continues to work with the JTF on renewed DIACAP certification so that the system can be reconnected to the central patient medical record via ICDB. Minor updates and maintenance was conducted on the CADS system as required.

Task 2

In support of continued DISA compliance over the project lifetime, Estenda will update all of the third-party infrastructure components required to versions that have documented support through 2012. These infrastructure components include Oracle Database Server, Weblogic Application Server, MIRTH Integration Engine, Struts Java Framework, etc. Estenda completed major infrastructure updates during this quarter; the completed solution is pending a final system test and then will be migrated to production in mid 2013.

Task 3

In support of the research team's clinical data capture and management Estenda has made significant upgrades to the platform's existing Survey and Study Management sub-modules. Specific improvements included (1) adding a user friendly tool for users to create their own subject data collection forms; (2) improving navigation features based on feedback from use on prior Diabetes Institute research studies; (3) adding native support for additional study randomization schemes; (4) improved ability to correct site data entry errors through a managed workflow; and (5) improving subject informed consent workflow. These important modifications will help support efficient, accurate and auditable data collection across the study's lifecycle. Improvement 1 is complete pending a final system test. Development items 2, 3, 4 and 5 are underway with a target completion date of 6/30/2013.

Task 4

The core diabetes data management platform of which CADS is a module requires modification in order to fully support its research mission. Core improvements include (1) adding functionality for authorized clinical staff to merge duplicate patients; (2) supporting for a broader range of Web Browsers; (3) allowing users to customize the patient information "snapshot" to best meet their individual mission; (4) improved graphing; and (5) adding new support to capture for patient reported use of alternative medications. These efforts will be initiated during the first quarter of the second year of this award, October 1, 2012 to December 31, 2012. Estenda has completed modifications to support a range of current, common web browsers. The remaining modifications will be addressed Jan 2013 - Jun 2013.

CDMP and CADS Maintenance and Enhancements: Additional Accomplishments Completion of CADS User Manual

The CADS User Manual (Appendix A) was completed in June 2012. Its use was demonstrated in a webinar that was held in June 2012. Additional minor changes are being made as deemed necessary.

Completion of Study Manager and the Study Manager User Manual

Study Manager is a standalone component within the Comprehensive Diabetes Management Program (CDMP) that was designed to track subjects' progress through an entire study and has the capacity to be customized to every study. Study Manager includes alerts to remind the research coordinators/project officer of tasks and due dates. Study Manager has been nearly completed for use in CADS. The Study Manager User Manual (Appendix B) was completed in June. Study Manager is undergoing some additional changes and the user manual will be modified to reflect changes once they are complete.

The list of algorithms has been expanded to include the combination of GLP-1 receptor agonists together with insulin, specifically basal insulin. One can have oral agents progressing to GLP-1, to insulin, or to GLP-1 + insulin. GLP-1 can progress to GLP-1 + insulin, and insulin can progress to GLP-1 + insulin.

Development of Questionnaires and Surveys, and Design of Focus Groups to Monitor the Response of Health Care Providers and Patients to the Use of the CADS System

Dr. David Rodbard has developed two questionnaires to be used in focus groups of 5 for providers who are participating in the study at one site. In order to keep a finger on the pulse of the study, especially with the providers who are randomized to CADS, Dr. Rodbard recommends that the first focus groups be held after training or exposure to the program and again at 6 months, 1 year, 18 months, and 24 months. Duration of each focus group

would be 30 minutes to minimize disruption in work flow. A focus group leader would be an MD or NP who has experience with the CADS and has seen the recommendations made by CADS for at least 3 patients.

- 1. The primary objectives of the CADS focus groups (Appendix C) would be to:
 - a. Identify any major problems either with operations or with the content of the system
 - b. Reduce the likelihood of provider and patient attrition
 - i. Empower the providers by soliciting and respecting their opinions.
 - ii. Their involvement or empowerment may help to sustain participation and reduce the risk of attrition.
 - iii. The interest and enthusiasm of the clinician may significantly affect the participation of the patients, and thus reduce the likelihood that the patients will withdraw from the study.
- 2. The primary objectives of the usual care focus group (Appendix 5) would be to:
 - a. Minimize the risk of skewing the results of the study in terms of differences between the CADS and usual care group by offering a focus group with 5 providers randomized to the usual care group.
 - Questions that would guide this focus group would include those that address more "generic" aspects
 of caring for people with diabetes, such as the use of professional guidelines or use of the current
 EMR

Essentially the same topics for discussion could be reviewed with the study participants (clinicians) after 6 months, 1 year, 18 months and 24 months.

None to date.

CONCLUSION

Diabetes mellitus is a significant cause of morbidity and mortality in the United States, and the leading cause of new blindness, chronic kidney disease, and non-traumatic amputation in the working-aged American population. Although the financial costs to individuals, communities, and health care systems are measurable, the devastating costs in terms of quality of life personal costs are not easily measured. A computer assisted decision support system that makes available the knowledge and expertise of endocrinologists to primary care providers who care for the majority of people with Type 2 diabetes has the potential to significantly improve the level of care provided to people with T2 DM, thus preventing or delaying the onset of and/or reducing the severity of diabetes-related complications. Reducing the risk and/or severity of complications promises to improve the quality of life for people with T2 diabetes and decrease the financial impact on the individual as well as both the military and civilian health care systems.

CADS is a web-based interactive application that enables primary care providers to aggressively and systematically use available medications to help their patients move increasingly and safely toward a level of glycemic control that minimizes their risk of developing diabetes-related complications and/or the severity of these complications. The extensive delays in and challenges to the implementation of the original study have made it impossible to begin the extension study as planned. The research staff at all three sites are making a consistent and concerted effort to meet enrollment goals. It is our hope that, once fully executed, the successes and lessons learned from this study can be applied to an even larger population of people with Type 1 and Type 2 diabetes, thus further mitigating the devastating financial and personal costs of poorly controlled diabetes mellitus.

REFERENCES

- 1. Diabetes Control and Complications Trial Research Group: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-term Complications in Insulin-dependent Diabetes Mellitus. (1993) *New Engl J Med, 329,* 977-986.
- 2. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., Kojima Y., Furuyoshi N., Shichiri M. (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res Clin Pract, 28,* 103-17.
- 3. UK Prospective Diabetes Study Group. (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 Diabetes: UKPDS 38. *Brit Med J, 317,* 703-712.
- 4. American Diabetes Association: Standards of Medical Care in Diabetes 2009 (2009) *Diabetes Care, 32 (Suppl 1),* S13-61.
- 5. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus. (2007) *Endocrine Practice, 13,* (Suppl. 1), 3-67.
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. (2005) N Engl J Med, 353, 2643-2653.
- 7. Holman R., Paul, SK, Bethel, MA, Matthews DR, and Neil, HA (2008) 10-Year Follow-up of Intensive Glucose control in Type 2 Diabetes. *N Engl J Med 359,* 1577-1589.
- 8. CDC Diabetes Cost-effectiveness Group. (2002) Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol reduction for type 2 diabetes. *J Amer Med Assoc, 287*, 2542-2551.
- 9. Diabetes Control and Complications Trial Research Group: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-term Complications in Insulin-dependent Diabetes Mellitus. (1993) *New Engl J Med*, *329*, 977-986.
- 10. Diabetes Control and Complications Trial Research Group. (1996). Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial [published erratum appears in (1997) JAMA 278: 25]. *JAMA*, *276*, 1409-1415.
- 11. Gilmer, T.P., (1997) The cost to health plans of poor glycemic control. *Diabetes Care, 20,* 1847-1853.
- 12. Herman, W.H., & Eastman, R.C. (1998) *Diabetes Care, 21 (Supplement 3),* C19-C24.
- 13. Menzin, J., Langley-Hawthorne, C., Friedman, M., Boulanger, L., & Cavanaugh, R. (2001) Potential short-term economic benefits of improved glycemic control. *Diabetes Care*, 24, 51-55
- Gray, A., Clarke, P., Farmer, A. & Holman, R. on behalf of the United Kingdom Prospective Diabetes Study (UKPDS) Group. (2002) Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: Cost analysis (UKPDS 63). *Brit Med J*, 325, 860-865.
- Curb, J.D., Pressel, S.L., Cutler, J.S., Savage, P.J., Applegate, W.B., Black, H., Camel, G., Davis, B.R., Frost, P.H., Gonzalez, N., Guthrie, G., Oberman, A., Rutan, G.H. & Stamler, J. (1996) Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic hypertension in the elderly program cooperative research group. *J Amer Med Assoc, 276,* 1886-1892.
- 16. Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlof, B., Elmfeldt, D., Julius, S, Menard, K., Rahn, K.H., Wedel, H. & Westerling, S. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomized trial. HOT Study Group. *Lancet*, *351*, 1775-1762.
- 17. Snow, V., Weiss, K.B. & Mottur-Pilson, C. for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. (2003) The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. *Ann Int Med, 138,* 587-592.
- 18. UK Prospective Diabetes Study Group. (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 Diabetes: UKPDS 38. *Brit Med J, 317,* 703-712.
- 19. Schrier, R.W., Estacio, R.O., Esler, A. & Mehler, P. (2002) Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. *Kid Int, 61,* 1086-1097.

- 20. Gaede, P., Vedel, P., Larsen, N., Jensen, G.V., Parving, H-H., & Pedersen, O. (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med, 348,* 383-393.
- 21. Holman R., Paul, SK, Bethel, MA, Matthews DR, and Neil, HA (2008) 10-Year follow-up after control of blood pressure in Type 2 Diabetes. *N Engl J Med 359*, 1565-1576.
- 22. Hoerger, TJ, Segel JE, Gregg, EW, and Saaddine, JB. (2008) Is glycemic control improving in the U.S. adults? *Diabetes Care 31*, 81-86.
- Rizza, R., Vigersky, RA., Rodbard, HW., Ladenson, PW., Young, WF., Jr., Surks, MI., Kahn, R., and Hogan, PF. (2003) A model to determine the workforce needs for endocrinologists until 2020. *J Clin Endo Metab, 88,* 1979-2003
- 24. Glasgow, R.E., Boles, S.M., McKay, H.G., Feil, E.G., & Barrera, M. (2003) The D-Net diabetes self-management program: long –term implementation, outcomes, and generalization results. *Prev Med, 36,* 410-419.
- 25. Izquierdo, R.E., Knudson, P.E., Meyer, S., Kearns, J., Ploutz-Snyder, R., & Weinstock, R.S. (2003) A comparison of diabetes education administered through telemedicine versus in person. *Diabetes Care, 26,* 1002-1007.
- 26. Peters, A.L. & Davidson, M.B. (1998) Application of a diabetes managed care program: the feasibility of using nurses and a computer system to provide effective care. *Diabetes Care, 21,* 1037-1043.
- 27. Alaoui A, Clement S, Khanafer N, Collmann J, Levine B, Mun S. (1999) Diabetes Home Monitoring Project. In: Nelson R, Gelish A, Mun S, eds. *Proceedings of the Pacific Medical Technology Symposium – PACMEDTek, Transcending Time, Distance and Structural Barriers. IEEE Computer Society,* 258-261.
- 28. Ober SK, Naito H, Low ME, Cutre KF, Crockett D, Skala MD, Asberry MT, Schumacher PO, Galen RS. (2000) A Web-based Internet System of Diabetes Management. *Diabetes, 49(Suppl 1),* Abstract #484.
- 29. Prendergast, J., Bagdade, J., Mayes, P, & Perrot, M. (2000) Diabetes mellitus management with internet augmentation. *Endocrine Society Annual Meeting, Abstract #1823,* Toronto, Canada.
- Vigersky, R.A. Anderson, T., Filmore, A., Thomas-Wharton, D., Novak, L., Heltzel, I.J., Smith, D., Kessler, C. & Galen, R.S. (2003) The use of telemedicine in the management of poorly controlled patients with diabetes mellitus. *Endocrine Society 85th Annual Meeting, Philadelphia, Pa.*
- Grant, RW, Wald, JS, Schnipper JL, Gandhi, TK, Poon, EG, Orav, EJ, Williams, DH, Volk, LA, and Middleton, B. (2008) Practice-linked online personal health records for type 2 diabetes mellitus. A randomized controlled trial. *Arch Intern Med 168*, 1776-1782.
- Smith, SA, Shah, ND, Bryant, SC, Christianson, TJH, Bjornsen SS, Biesler, PD, Krause, K, Erwin, PJ, and Montori VM. (2008) Chronic care model and shared care in diabetes: Randomized trial of an electronic decision support system. *Mayo Clin Proc* 83, 747-757.
- Rodbard D, Vigersky RA. (2004) Development of a Computer Assisted Clinical Decision Support System (CADS) to Support Clinicians in Management of Patients with Type 1 and Type 2 Diabetes Mellitus. *Diabetes Technology Society*, Annual Meeting.
- 34. Pernick NL, Rodbard D. (1986) Personal computer programs to assist with self-monitoring of blood glucose and self-adjustment of insulin dosage. *Diabetes Care. 9,* 61-9.
- 35. Albisser AM (1990) Six generations of the insulin dosage computer: a new clinical device for diabetes selfmanagement through specialized centres. *Horm Metab Res Suppl. 24,* 140-4.
- 36. Holman RR, Smale AD, Pemberton E, Riefflin A, Nealon JL. (1996) Randomized controlled pilot trial of a handheld patient-oriented, insulin regimen optimizer. *Med Inform (Lond).* 21, 317-26.
- 37. Berger MP, Gelfand RA, Miller PL. (1990) Combining statistical, rule-based, and physiologic model-based methods to assist in the management of diabetes mellitus. *Comput Biomed Res.* 346-57.
- 38. Lehmann ED, Deutsch T, Roudsari AV, Carson ER, Benn JJ, Sonksen PH. (1992) An integrated approach for the computer-assisted treatment of diabetic patients on insulin. *Med Inform (Lond)*. *17*, 105-23.
- 39. Chiarelli F, Tumini S, Morgese G, Albisser AM. (1990) Controlled study in diabetic children comparing insulindosage adjustment by manual and computer algorithms. *Diabetes Care. 13*, 1080-4.
- Meigs, J.B., Cagliero, E., Dubey, A., Murphy-Sheehy, P., Gildesgame, C., Chueh, H., Barry, M.J., Singer, D.E., Nathan, D.M. (2003) A controlled trial of web-based diabetes disease management. *Diabetes Care, 26,* 750-757.
- 41. Shea S, Weinstock, RS, Teresi, JA, Palmas, W, Starren, J, et al. for the IDEATel Consortium (2009) A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved

patients with diabetes mellitus: 5 year results of the IDEATel study. J Am Med Inform Assoc e-pub on April 23, 2009 doi:10.1197/jamia.M3157

- 42. <u>Salzsieder E, Augstein P, Vogt L, Kohnert KD, Heinke P, Freyse EJ, Azim Ahmed A, Metwali Z, Salman I, Attef O</u> (2007) Telemedicine-Based KADIS(R) Combined with CGMS Has High Potential for Improving Outpatient Diabetes Care. J Diabetes Sci Technol. 4:511-21.
- 43. Bosworth HB, Olsen MK, Dudley T, Orr M Goldstein MK, Datta SK, McCant F, Gentry P, Simel DL, Oddone EZ (2009) Patient education and provider decision support to control blood pressure in primary care: a Cluster randomized trial. Am Heart J 157: 450-456.
- 44. Roumie, CL, Elasy, TA, Greevy, R, et al.(2006) Improving blood pressure control through provider education, provider alerts, and patient education: a cluster-randomized trial. *Ann Intern Med 145*, 165-175.Sidorov J, Shull, R, Tomcavage, J, Girolami, S, Lawton, N, and Harris, R. (2002) Does diabetes disease management save money and improve outcomes? *Diabetes Care 25*, 684-689.
- 45. Mazze RS, Etzwiler DD, Strock E, Peterson K, McClave CR 2nd, Meszaros JF, Leigh C, Owens LW, Deeb LC, Peterson A, et al. Staged diabetes management. Toward an integrated model of diabetes care. Diabetes Care. 1994 Jun;17 Suppl 1:56-66.
- 46. Mazze RS, Strock ES, Simonson GD, and Bergenstal RM. Staged Diabetes Management. Staged diabetes management: a systematic approach. Chichester: John Wiley & Sons, 2006.
- 47. Ginsberg BH, Tan MH, Mazze R, Bergelson A. Staged diabetes management:Computerizing a disease state management program. J Med Syst. 1998, Apr; 22 (2):77-87. 49.

References for algorithms (not listed in body of report):

- 1. Rodbard D, Vigersky RA. Design of a decision support system to help clinicians manage glycemia in patients with type 2 diabetes mellitus. J Diabetes Sci Technol. 2011 Mar 1;5(2):402-11. PubMed PMID: 21527112; PubMed Central PMCID: PMC3125935.
- Inzucchi SE, Bergenstal RM, Buse JB, et al. (2012) Management of hyperglycaemia in type 2 diabetes: a patientcentered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596
- 3. Nathan DM, Buse JB, Davidson MB, et al. (2009). Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17–30.
- Rodbard HW, Jellinger PS, Davidson JA, et al (2009) Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 15: 540 – 559. Erratum 15:768-70.
- 5. DOD/VA algorithm: David Aron, MD, MS; Paul Conlin, MD; John R. Downs, MD; Mercedes Falciglia, MD; Linda Haas, PhC, RN, CDE; Debbie Khachikian, Pharm D; Leonard Pogach, MS, MBA (Co-Chair); Ruth Weinstock, MD, PhD, Alan Douglass, MD; Curtis Hobbs, MD (Co-Chair); Jack E. Lewi, MD; James McCrary, D.O.; Robert Vigersky, MD; Susan Walker, PhD, RN, CDE, Carla Cassidy, RN, MSN, NP, Ernest Degenhardt, MSN, RN, ANP-FNP; Angela V. Klar, MSN, RN, ANP-CS, Oded Susskind, MPH, Martha D'Erasmo, MPH; Rosalie Fishman, RN, MSN, CPHQ; Sue Radcliff. VA/DoD clinical practice guideline for the management of diabetes mellitus. http://guideline.gov/content.aspx?id=24192

COMPUTER ASSISTED DECISION SUPPORT

For Management of Patients with Type 2 Diabetes

CADS

Quick Reference User Guide

June 13, 2012

Version 1

NOTE:

This software is being introduced as part of a research study that has been approved at the Walter Reed National Military Medical Center (WRNMMC), Wilford Hall Ambulatory Surgery Center (WHASC), and the University of Hawaii (UH).

In order to main the integrity of the study, only physicians and other providers who have been enrolled in the study, consented, and randomized to CADS (the intervention arm) are authorized to use this program.

Table of Contents

Page

Key Personnel	2
Contact Information	3
Introduction to CADS	5
CADS: Key Elements	6
Important Things to Remember	7

Using CADS to get Treatment Recommendations

0	Login9
0	Select Patient10
0	Enter the CADS System11
0	Run Analysis12
0	Enter the target A1C14
0	Set Date Range for Analysis15
0	View Laboratory Results16
0	Enter/View Medications16
0	Diagnoses that May Affect Recommendations17
0	Identify/Resolve Potential Issues
0	View Recommendations for Therapy19
0	CADS results: Caveats
0	Summary of Problem Areas23
0	View Glucose Graphs and Data, 24
0	Bibliography

Key Personnel

Walter Reed National Military Medical Center (WRNMMC)

- PI: Dr. Robert Vigersky COL MC USA
- RC: Dr. Mary Chellappa
- Program Manager: Dr. Susan Walker

Wilford Hall Ambulatory Surgery Center (WHASC)

- PI: Dr. Mark True COL MC USAF
- RC: Ms, Peggy Smith

University of Hawaii (UH)

- PI: Dr. Sven Bursell
- Associate Investigator: Dr. Joe Humphry
- RC: Ms. Kathleen Connelly and Ms. Kanani Kemp

Contact Information

WRNMMC

Mary Chellappa

Email: mary.chellappa@med.navy.mil Cell: 301-424-2499 Work: 301-319-2871

Robert Vigersky

Email: Robert.vigersky@med.navy.mil Work: 301-319-2314

Susan Walker

Email: susan.walker@med.navy.mil Work: 301-319-2867 Cell: 301-919-2608

Sara Salkind

Email: sara.salkind@med.navy.mil Work: 301-319-2873 Cell: 302-598-3792

RJ Kedziora

Email: rkedziora@estenda.com

WHASC

Peggy Smith

Email: peggy.smith.9.ctr@us.af.mil Cell: 210-854-2982 Work: 210-292-3546

Mark True

Email: mark.true@amedd.army.mil

UH

Sven-Erik Bursell Email: svenerik@hawaii.edu Cell: 808-692-0842

Joe Humphry

Email: jhumphry@hawaii.rr.com

Kanani Kemp

Email: kanani@tipg.net Cell: 808-381-2075

Kathleen Kihmm Connolly

3

Email: Kihmm@hawaii.edu Cell: 808-342-2188 Work: 808-584-8580 Work: 808-956-2514

INTRODUCTION TO CADS

Primary Purpose of CADS:

- To enhance primary care providers' (PCPs) ability to help their patients on basal insulin, oral hypoglycemic agents, non-insulin injections, or diet and exercise to achieve and maintain glycemic control.

Reasons for failure to achieve glycemic goals:

- Patients
 - Insufficient education and/or inability to use self monitoring of blood glucose (SMBG) effectively
 - Inability or lack of resources to download glucose data at home or in clinics
- Providers
 - Inadequate amount of time allowed for PCP to identify patterns and discuss with patients
 - Overwhelming number of single and combination agents available to treat hyperglycemia
 - Clinical inertia

Difficulties in maintaining glycemic goals:

- Patients
 - Patients do not understand how to use SMBG to make lifestyle changes, e.g. diet and physical activity
 - Infrequent use of SMBG
 - Inefficient use of SMBG efficiently (i.e., pre and post prandial, aka structured or paired testing)
 - o Inability or unwillingness to download SMBG data
- Providers
 - Not feasible to download SMBG data in Clinic No time available to analyze SMBG data
 - Therapy not adjusted frequently enough Numerous medications and combinations are available, but most physicians use only a subset
 - Cannot access literature, guidelines, algorithms

CADS is the result of the development of a comprehensive set of algorithms by two endocrinologists with combined experience of more than 50 years as diabetologists. CADS makes recommendations, but the provider determines treatment!

CADS: Key Elements

- Patients will
 - Perform SMBG 2-4X/day, 4X/day once a week, and 8X/day once a month.
 - Upload glucometer every 2 weeks using a device called *i*Metrikus and a landline telephone (WR & WH) or using a cell phone and a glucometer called MyGlucoHealth (UH).
- Research Coordinator (RC) at WRNMMC & WHASC¹ will
 - Upload into CADS the necessary information for CADS to work, e.g. current medications, current laboratory values, current A1C level, and after discussion with the PCP, target A1C level for each patient.
 - Send provider's patient's BG data to coincide with patient's quarterly visits &/or t-cons.
 - Send providers the recommendations made by CADS for that set of data.
- CADS will
 - Provide statistics and graphs that identify glucose values and patterns
 - Make recommendations for therapy
 - Note: If 10% or more of the patient's BG levels are < 60 mg/dL, CADS will provide recommendations that address the hypoglycemia.
 - Addressing hypoglycemia is always CADS first consideration!
 - Identify major types of clinical problems &/or co-morbid conditions that would be contraindications to certain medications

Benefits of CADS

- Data available for you the clinician at the time of clinic visits and telephone consultations
- Quick, easy
- Automated access to SMBG data
- Automated access to laboratory data
 - A1C, Liver function tests, Renal function tests, Lipid panels
- Automated access to diagnoses
 - Possible contraindications to various medications identified
- Record of previous medications
 - Record of previous adverse events and side effects
- Ability to export or print a file for inclusion in the patient's medical record

Features which may be added at a later date

- Automated generation of a clinic note
- Automated generation of an electronic prescription
- Ability for patient to view SMBG data, graphs and statistics

IMPORTANT THINGS TO REMEMBER

- <u>Only</u> applicable for *Type 2 Diabetes* patients who are using diet and exercise, oral meds, non-insulin injectables, and basal insulin
- <u>Not</u> for Type 1 Diabetes
- Not for acute therapy, e.g. DKA, hyperosmolarity, or hospitalized patients
- <u>Not</u> for use in children, adolescents, for diabetes during pregnancy or for gestational diabetes

Each physician/clinician must exercise their clinical judgment in view of the total clinical situation.

If in doubt, seek additional information and consult a colleague or a <u>specialist!</u>

USING CADS TO GET TREATMENT RECOMMENDATIONS

- 1. Login
- 2. Select Patient
- 3. Enter the CADS System
- 4. Run Analysis
- 5. Enter the target A1C
- 6. View Recommendations for Therapy
 - View multiple alternatives
 - Select preferred recommendation
 - Modify as desired
 - Record your comments re your decision
 - "Sign off" on recommendations
- 7. View other resources
 - Literature, Guidelines, Prescribing Information, Formulary, Costs of Medications

STEP 1: LOGIN

Welcome to the						
Comprehensiv	e Diabetes Management Program					
Please er	nter your Username and Password to continue Username: Password: Login Forgot Password?					

Each user will receive a Username and Password to log in to the system.

STEP 2: SELECT PATIENT

						alphanumeric study ID code
						between the first (site-clinic)
Patient Sear	ch					and last names (provider-
Tutient ocur	ch .					arm-patient#). Use part of
						that code as the patient
Patient Search ID		Leet News		First Name:		search ID so you can quickly
(Last Name):		Last Name:				find each patient without
Patient SSN:		Sponsor SSN:	_			entering entire code. You
Date of Birth:		Gender:		Team: (All)	~	can enter date of entry into
	mm/dd/yyyy)					study for DoB.
		Find Patients	Clear			

Split the patient's

Select the patient by entering the Last Name or First Name (Arrow #1). Then select the [Find Patients] button.

	Patient Searc	h - Windov	vs Internet	Explorer	provided by	WRNMMC E	Bethesda	_ 7
)© - @I	nttp://demo.estend	a.com/cdmp/pati	ientSearch.do				🖌 🗲 🗙 Google	ρ.
le <u>E</u> dit ⊻ie	ew F <u>a</u> vorites <u>T</u> oo	ols <u>H</u> elp						
🔅 🍘	MP - Patient Search						🟠 🔹 📾 🕤 🖶 🖻 Pag	ge 🕶 🎯 T <u>o</u> ols 👻 '
CDMP - Dia	betes Demo (5.2 B	leta)				Search	User Pref Help Log Out	~
	Patient Search	a						
	Patient Search ID							
	(MRN):		Last Name: 0	CadsTest	First Name:	Mixed		
	Date of Birth: (mi	m/dd/yyyy)	Gender:	*	Team:	(All) 💙		
			Find Pa	ationte	Clear			
			- HING P	auents	Clear			
							1 - 1 of 1	
							1-1011	
	Patient Sear	rch Results First Name	Date of Birth	Gender	Team Name	Patient Search ID		
	CadsTest					(MRN)		
		Mixed	01/17/1972	M	Demo	CadsTestM		
		Mixed	01/17/1972	M	Demo	CadsTestM		
		Mixed	01/17/1972	M	Demo	CadsTestM		
		Mixed	01/1//19/2	M	Demo	CadsTestM		
		Mixed	01/17/19/2	M	Demo	CadsTestM		
		Mixed	01/1//19/2		Demo	CadsTestM		
		Mixed	01/1//19/2		Demo	CadsTestM		
		Mixed	011/719/2		Demo	CadsTestM		
		Mixed	011/719/2	M	Demo	CadsTestM		
r: cadsdemo		Mixed		M	Demo	CadsTeatM	For Official Use Only	

To select a specific patient, simply click on that patient's Last Name (CadsTest) or First Name (Mixed). For this example, the patient's name is Mixed CadsTest, for data entry purposes the patients name will be First name (site-clinic) and last name (provider-arm-patient#).

STEP 3: ENTER THE CADS SYSTEM

After selecting the Patient, you will be ready to enter the CADS System.

At this point, you will need to select the Target A1c value for this patient. Remember, this needs to be done every time you run a new CADS analysis (Arrow #1). You will also enter the Start Date and End Date for the range of glucose data that you are using for this CADS analysis (Arrow #2).



STEP 4: RUN ANALYSIS

	CDMP - Diabet	es Demo (5.2 Beta) Search User Pref Help Log Out
	Patient Menu Patient Info D-Clinical		lysis Setup: Mixed CadsTest (01/17/1972)
- <i>-</i>	E-Home Monitoring E-CADS		nalysis Setup formation
3	open all close all		○ Type 1 ⓒ Type 2 ○ Gestational
		* Gender: * Age:	○ Female ③ Male 40
		* Target A1C Value:	
		* Select range of dates for analysis:	Start Date End Date View Glucose Graph 2/29/2012 I Sr31/2012 I

Select <u>CADS</u> (Arrow #3) from the menu on the bottom of the navigation panel at the left of the screen.



- After selecting CADS, the <u>New Analysis</u> choice will open. To perform a <u>New Analysis</u> of the available data, select <u>New Analysis</u> (Arrow # 4)
- You can also select run analysis at the bottom of the page.

CADS History:	Mixed CadsTest (01/17/	/ 1972)		
CADS History			Setup New Analysis	
CADS Analysis Date	Date Range Evaluated	Performed By	Action	
05/31/2012	05/01/2009 - 12/31/2009	cadsdemo	Review & Sign Delete	
11/15/2011	01/01/2011 - 05/18/2011	cadsdemo	View	
11/15/2011	01/01/2011 - 05/31/2011	cadsdemo	View	
11/15/2011	01/01/2011 - 05/15/2011	cadsdemo	Review & Sign Delete	
11/15/2011	01/01/2011 - 05/31/2011	cadsdemo	Review & Sign Delete	
11/15/2011	01/15/2011 - 05/05/2011	cadsdemo	Review & Sign Delete	
11/15/2011	01/01/2011 - 05/06/2011	cadsdemo	View	
11/15/2011	01/01/2011 - 05/06/2011	cadsdemo	Review & Sign Delete	
11/14/2011	01/07/2011 - 05/26/2011	cadsdemo	View	
11/10/2011	01/07/2011 - 05/31/2011	cadsdemo	Review & Sign Delete	
11/10/2011	01/07/2011 - 05/31/2011	cadsdemo	Review & Sign Delete	
11/09/2011	01/07/2011 - 05/31/2011	cadsdemo	Review & Sign Delete	
11/04/2011	01/01/2011 - 05/01/2011	admin	Review & Sign Delete	
10/27/2011	01/28/2011 - 05/31/2011	admin	Review & Sign Delete	
10/27/2011	01/03/2011 - 03/30/2011	admin	Review & Sign Delete	
10/26/2011	01/31/2011 - 05/31/2011	admin	View	
10/26/2011	01/31/2011 - 05/31/2011 02/05/2011 - 05/31/2011	admin	Review & Sign Delete	
10/26/2011	01/31/2011 - 05/31/2011	admin	View	
10/25/2011	01/02/2011 - 03/30/2011	admin admin	Review & Sign Delete	
10/25/2011	01/01/2011 - 05/31/2011	cadsdemo	View	
10/06/2011	01/01/2011 - 05/31/2011	cadsdemo	View	
09/27/2011	01/01/2011 - 03/31/2011	cadsdemo	Review & Sign Delete	
09/23/2011	01/01/2011 - 05/31/2011	cadsdemo	Review & Sign Delete	
09/23/2011	01/01/2011 - 05/31/2011	cadsdemo	View	
09/20/2011	06/20/2010 - 09/20/2011	admin	Review & Sign Delete	
08/15/2011	05/15/2011 - 08/15/2011	admin	Review & Sign Delete	
07/25/2011 06/20/2011	04/25/2011 - 07/25/2011	admin admin	Review & Sign Delete	
06/20/2011	03/20/2011 - 06/20/2011 03/20/2011 - 06/20/2011	admin	Review & Sign Delete Review & Sign Delete	
06/20/2011	03/20/2011 - 06/20/2011 01/01/2011 - 06/15/2011	admin	View	
06/07/2011	02/25/2011 - 05/25/2011	admin	Review & Sign Delete	
05/25/2011	02/25/2011 - 05/25/2011	admin	View	
08/23/2010	05/23/2009 - 08/23/2009	admin	Review & Sign Delete	
08/20/2010	05/20/2009 - 08/20/2009	admin	Review & Sign Delete	
08/18/2010	01/18/2009 - 07/18/2009	admin	Review & Sign Delete	
08/18/2010	01/18/2009 - 06/18/2009	admin	Review & Sign Delete	
08/18/2010	05/18/2009 - 08/18/2009	admin	Review & Sign Delete	
08/05/2010	01/05/2009 - 04/05/2009	admin	Review & Sign Delete	
07/23/2010	04/23/2009 - 07/23/2009	admin	View	
07/22/2010	04/22/2009 - 07/22/2009	admin	View	_
07/04/2010	01/01/2009 - 04/01/2009	admin	Review & Sign Delete	
07/04/2010	04/01/2009 - 07/31/2009	admin	Review & Sign Delete	
07/04/2010	04/04/2009 - 07/04/2009	admin	Review & Sign Delete	
	CADS BI	bliography, Algorithms a	and Guidelines	

To view a previously performed analysis, select <u>View</u> under Action (Arrow #1). You can also select background reading material is available (Arrow #2)

STEP 5: ENTER THE TARGET A1C

- Diabetes Demo	(5.2 Beta) Search User Pref Help Log
CADS An	alysis Setup: Mixed CadsTest (01/17/1972)
nitoring CADS	Analysis Setup
nalysis Patient 1	Information
* Diabetes	
close all Type	○ Type 1
* Gender	○ Female ④ Male
* Age	40
* Targe	t 0 60 0 65 0 7.0 0 7.5 0 80 0 85 0 9.0
A1C Value	
* Selec	
range o dates fo	
analysis	
Most Re	cent Patient Labs
* A10	
	06/29/2010 2. View Past Results
* ALT	Date Result
	06/29/2010 🗷 67 View Past Results
* Creatinine	Date Result
	06/29/2010 2 .9 View Past Results
Current	Medications
Curren Regimen	Select a medication, dosage, sig/frequency and enter the instructions. Click the Add Medication link to add to the medication list. Optionally, select any sid effects for the current medications and check the Stop Medication checkbox if you would like to discontinue the medication effective today.
	Medication Dosage Med Sig/Frequency Side Effects Stop Medication Add Medication
Medication	Enter past medication(s) that are no longer used. These will be excluded from the algorithm. Select a medication from the drop down to add it to the list.
History	Past Medication
Diagnos	es that may affect recommendations
Diagnoses	
	Renal Hepatic Cardiac Gastrointestinal
*=	Required Field (Run Analysis) Cano
adsdemo	Contact Administrator For Official
TI, Demo, IHS, Joslin, WRAM	
rity Audit Report	

Factors considered for generation of recommendations:

- **Patient Information** (diabetes type, gender, age, target A1C, range of dates for analysis)
- Glucose Data
- Laboratory Results (A1C, ALT, creatinine)
- Current and Past Medications (drugs, dose, frequency, side effects)
- Comorbid Conditions

Setting Target A1C and Glucose Values

	nformation		
* Diabetes Type:			
* Gender:	◯ Female ④ Male		
* Age:	**		
* Target A1C Value:	O 6.0 ○ 6.5 ○ 7.0 ④ 7.5 ○ 8.0 ○ 8.5 Warning: Changing the Target A1C will alter the		ose Ranges
* Target Glucose		Glucose Lower Limit *	Glucose Upper Limit *
Values:	AlDay	80	120
	Before Breakfast	95	170
	After Breakfast	95	250
	Before Lunch	95	170
	After Lunch	95	250
	Before Dinner	95	170
	After Dinner	95	250
	Bed Time	95	150
	Night	95	150
* Select range of	Start Date End Date	View Glucose Gr	aph
dates for analysis:	5/1/2009		
			😜 Internet

Setting the target A1C value (Arrow # 1) will automatically set the upper and lower limits of the target range for each of 8 separate times of day, and for the whole day ("AllDay").

۸

If you, the clinician, wish to modify any of these values, simply enter a value into the text box.

In general, the higher the target A1C is set, the higher the upper and lower limits of the target range will be in order to minimize risk of hypoglycemia.

For example, notice how the Glucose Lower Limit and Glucose Upper Limit change now that the Target A1c is set at 9.0 instead of 7.5.

*Target 06.0 06.5 07.0 07.5 08.0 08.5 09.0 A1C Value: Warning: Changing the Target A1C will alter the Target Glucose values. - Hide Target Glucose Ranges * Target **Time Period Glucose Lower Limit Glucose Upper Limit *** Glucose AllDay 80 120 Values: 275 Before Breakfast 110 After Breakfast 110 275 110 275 Before Lunch 275 After Lunch 110 110 275 Before Dinner 275 110 After Dinner 110 250 Bed Time 110 250 Night





This Graph Glucose over time will be displayed automatically when you select a date range for glucose data analysis.

Enter/View Laboratory Results

Most Rece	nt Patient Labs
* A1C:	Date Result 06/29/2010 9.2 View Past Results
* ALT:	Date Result 06/29/2010 City Of Comparison Results
* Creatinine:	Date Result 06/29/2010 Image: Second

Enter/View Current Medications

Current	Medications								
Curre Regime									
	Medication Dosage	Med Sig/Frequency Side Effects Stop Medication Action							
		Add Medication							
Medicatio Histor		r used. These will be excluded from the algorithm. Select a medication from the drop down to add it to the list.							

This patient is taking two oral diabetes medications, Metformin and Acarbose. These were added by selecting the Medication in the dropdown menu, selecting the dosage, selecting the frequency and then clicking on the Add Medication button. If a mistake is made, you can remove the medication by clicking on the X next to the listing. The analysis also takes into account that this patient was previously on Rosiglitazone and will not include that medication in the recommendations.

Medication	Dosage	Med Sig/Freque	ncy Side Effects	Stop Medi	cation Action Add Medication
Metformin	1000 mg	Twice a day	None, at present time	•	×
Acarbose	25 mg	After dinner	~		×
			Cramping Bloating	X	

Diagnoses that May Affect Recommendations

	Renal	Hepatic	Cardiac	Gastrointestinal	
	BENIGN HYPERTENS	IVE KIE 🗸	~	~	*
E	BENIGN HYPERTENSIVE K	IDNEY DISEASE		×	

For each drop menu (Renal, Hepatic, Cardiac, Gastrointestinal) select any pertinent diagnoses that this patient currently has to be factored into the CADS analysis.

After you have confirmed that the information is accurate, select <u>Run Analysis</u>.

POTENTIAL ISSUES

The following items must be corrected or checked: Anonymous Study Id must be set to Setup New Analysis. Please contact your study coordinator. CADS Study Identifier is not set. If this patient is in the study, please set the CADS Study Id before continuing.							
CADS History: High - All Periods CADS (01/01/1972)							
CADS History			Setup New Analysis				
CADS History CADS Analysis Date	Date Range Evaluated	Performed By	Setup New Analysis Action				
	Date Range Evaluated 01/01/2010 - 03/01/2010	Performed By admin					

Two messages may be displayed at the top of the <u>CADS History</u> page. If the Anonymous Study ID has not been set, the message in red will be displayed. You will not be able to continue until it has been entered.

- If you see the **CADS Study Identifier** warning and the patient is part of the study, do not continue! Contact Sara Salkind or Susan Walker to make sure the patient's study identifier is properly configured

STEP 6: VIEW RECOMMENATIONS FOR THERAPY

OS Results for 05/31/20	J12: Mixed Ca	dsTest (DOB 01/17/197	2)			
Recommendations	Glucose Summary	Glucose Log Book	Glucose G	raphs	Input Da	ita
Recommendati	ON (1 of 3)				Range An 01/2009 - 12	
	s rare. Should no obv	e hypoglycemia with th ious cause(s) be found or Acarbose.		A1C D Type Lab		06/29/201
(Click to view Formulary Prescribing Information Patient Information or Add Comments)					cted 7.1	00/20/201
	Accept Recommen	dation	/iew Next	Target Proble	ms	
	Sign				Breakfast	Problem High
		mental clinical decision supp suitability of the recommendation			Breakfast Lunch	Low
for your patient. If in doubt regarding the safety and appropriateness of the recommendations, use your best judgment.					unch	Low
					Dinner	Low
his recommendation is based	on:			Bed T	ime	High
ne current medication regimen lycemic goals for the patient				Night * less	than 20 res	High ults in period

Analysis of patient information, labs, medications, diagnoses, date range, and A1C (actual, predicted, and target) generates a *<u>Recommendation</u>*. You can <u>*Accept Recommendation*</u> and <u>*Sign*</u> or select <u>*View Next* (*Recommendation*)</u>.

The links below the recommendation (Formulary | Prescribing Information | Patient Information or Add Comments) provide more information for you or your patient and allow you to write comments.

Items shown on the right hand side of the Recommendations screen identify the

- Range of dates for SMBG data used in analysis
- Current A1C Lab value and date
- Predicted A1C based on SMBG Values
- Selected Target Value for A1C as specified by the clinician and entered into CADS Setup

34

Date Range Analyzed 05/01/2009 - 12/31/2009								
1	A1C Data							
	Туре	Valu	e					
	Lab	9.2	06/29/20)10				
	Predicted	7.1						
	Target	7.5						
F	Problems							
	Period Problem							
	Before Brea	kfast	High					
	After Break							
	Before Lunc	Low						
	After Lunch	Low						
	Before Dinn							
	After Dinner	Low						
	Bed Time		High					
	Night High							
	* less than 20 results in period							

Problems shows a list of Problems identified at each of 8 time periods per day

- NOTE: If a time period has less than 20 values – this is flagged with an asterisk (*) because there are insufficient results to make a conclusive recommendation. A recommendation will still be made but with significantly less confidence.

Second recommendation (2 of the 3 that CADS will provide)



The "View Previous" button means "View Recommendation # 1" (the prior recommendation) The "View Next" button means "View Recommendation # 3" (the next recommendation) After viewing all of the potential recommendations you will see this screen. The provider can enter their own recommendation at this point and click the "Sign" button.

Recommendation

No further recommendations have been made.

If none of the suggested changes were acceptable, please add your recommendation as a comment below and click the Sign button.

Comments:

This patient needs to go on basal insulin. Insulin was not included among the various recommendations provided by the CADS system. The patient has an A1C of 9.2 and has failed to achieve goal when using two- and three-drug combinations. I will discontinue the oral agents and use long acting (basal) insulin analogs, especially in view of her age, duration of diabetes, and her co-morbidities.

View Previous

ACCEPT AND SIGN



Reviewing Signed CADS Analysis

Once signed, a CADS Analysis **cannot be changed** – when viewing you can see the recommendation that has been accepted.
STEP 7: CADS RESULTS: CAVEATS

Caveats include the rationale for the recommendation, as well as any contraindications or caution that needs to be addressed.

Caveats	The blue type indica
1) This recommendation is based on: the current medication regimen glycemic goals for the patient data analysis past medication history absence of clear contraindications from laboratory studies or existing diagnoses codes	these are sections c caveats that link to information within
 Treatment of patients with significant renal dysfunction (creatinine above 2.0 mg/dl) is not recommended. 	on the blue section
3) Metformin is known to be substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus, patients with serum creatinine levels above the upper limit of normal for their age should not receive metformin. Because aging is associated with reduced renal function, metformin should be used with caution as age increases. Care should be taken in dose selection and should be based on careful and regular monitoring of renal function.	more information a of the caveats that highlighted in blue.
4) GLP contraindicated because of the following: A GLP-1 should not be used in patients with severe renal impairment or end-stage renal disease and should be used with caution in patients with renal transplantation. Caution should patients be applied when initiating a GLP-1 agonist or escalating the dose of a GLP-1 agonist in patients with moderate renal failure	
Secretagogue contraindicated because of the following: The metabolism and excretion of an insulin secretatogogue may be slowed in patients with impaired renal impairment and cause hypoglycemia	
6) There appears to be insufficient SMBG data to make a definitive recommendation. A minimum of 20 readings is required to accurately assess that there is a problem. Additional testing is recommended in the following period(s) that do not have sufficient data: Before Dinner.	
7) The A1C and SMBG values are not consistent. This may be due to the fact that both the A1C and the SMBG values are a bit out of date. Accordingly, additional SMBG testing is advised. Please consider the following: meter inaccuracy, possibility of hemoglobinopathy, anemia or recent blood transfusions, or hyper- and/or hypoglycemia occurring at times of day when SMBG is not being performed.	
8) The last A1C lab value is greater than 30 days old. This may not accurately reflect the SMBG data. Consider	

8) The last A1C lab value is greater than 30 days old. This may not accurately reflect the SMBG data. Consider ordering a new A1C value.

9) The SMBG data is older than 7 days.

cates that of the o additional CADS. Click n to get about any are ١.

STEP 8: PROBLEM SECTION

The problems section repeats the areas that were previously identified by showing the patterns and periods of hypoglycemia, hyperglycemia, and/or target glucose values.

A1C Data				
Туре	Valu	e		
Lab	9.2	06/29/20	10	
Predicted	7.1			
Target	7.5			
roblems				
Period		Problem		
Before Brea	kfast	High		
After Break	fast			
Before Lunc	ch	Low		
After Lunch		Low		
Before Dinn	er *			
After Dinner	r	Low		
Bed Time		High		
Night		High		
* less than	20 res	sults in peri	od	

23

STEP 8: VIEW GRAPHS AND INFORMATION PROVIDED BY THE GLUCOSE DATA

CADS DISPLAYS

- Glucose log book
- Statistics: Mean, % Low, % High, by time of day
- Graphs:
 - Glucose by Date
 - Glucose by Time of Day
 - Glucose in Relationship to Meals
 - Glucose by Day of the Week
 - Pie Charts: % High, % Low, % in Target range
 - "Stacked bar charts": a more compact way to display data from Pie-charts
 - Two dimensional display vs. date and time of day

SMBG DATA

- Glucose Summary
- Graphs
 - By Date
 - By Time of Day
 - By Day of the Week
 - Pie Charts
 - Stacked bar charts

Glucose Log Book

Recomme	ndations	Glucose	Summary	Gluc	ose Log E	Book	Glucose	Graphs	Input Data	
Date	Daily Average	Before Breakfast	After Breakfast	Before Lunch	After Lunch	Before Dinner	After Dinner	Bedtime	Night	Total Daily
T. D		07:00 AM -	09:00 AM -	11:30 AM -	12:30 PM -	03:00 PM -	06:00 PM -	09:00 PM -	11:00 PM -	Reading
Time Period		09:00 AM	11:30 AM	12:30 PM	03:00 PM	06:00 PM	09:00 PM	11:00 PM	07:00 AM	
Range		95 - 170	95 - 250	95 - 170	95 - 250	95 - 170	95 - 250	95 - 150	95 - 150	
05/24/2009	142	178			120		149		91 174	
05/25/2009	164	145			118 246		95		217	
05/26/2009	128		121		136					
05/27/2009	186	161 212								
05/28/2009	155	193		162			111			
05/29/2009	146			119			177		142	
05/30/2009	132				134		131			
05/31/2009	178	157	258		162		125		158 210	
06/01/2009	176	231			152		146			
06/02/2009	235		164		354		188			
06/03/2009	192								224 161 191	
06/04/2009	141	146		166			113			
06/05/2009	94		87				101			
06/06/2009	163						152		174	
06/07/2009	137	154					120			
06/08/2009	155	150			141		175			
06/09/2009	255							255		
06/10/2009	187								187	
06/11/2009	139	145		121			153			
12/06/2009	150	201		1	148	1	109		144	
12/07/2009	157	181							134	
12/08/2009	162				162					
12/09/2009	174								174	
12/10/2009	150	144		132			175			
12/11/2009	153		98			150			168 197	
12/12/2009	132			119			109 157		143	
12/13/2009	178				250		129		155	
12/14/2009	180	152							209	
12/15/2009	152		143		156		157			
12/16/2009	187	193							182	
12/17/2009	141	94		165			107		201	
12/18/2009	100			117			55		129	
12/19/2009	125				127		91	157		
12/20/2009	111	132			75		128			
12/21/2009	193	152					120		237	
12/22/2009	131		170				93 131			
12/23/2009	157				162		153			
12/24/2009	118	92		137			148	95		
12/25/2009	98	02					67		129	
12/26/2009	124	103					145		120	
12/27/2009	131	103			142		139			
12/28/2009	170	210			102 204		159			
12/29/2009	142	210			102 204		104			
12/29/2009	142				140	166	139		92	
12/30/2009	129	420		422		166	227	402	52	
	163	130	27	132	00	7	227	163	110	5
# Readings Average	154	117 161	37	53 130	80	150	156 135	26	119 166	5

of
Readings/time
period and
Average Reading
are the bottom
values in Glucose
Log Book

Red = High Blue = Low Black = In Target

VIEW GLUCOSE GRAPHS AND DATA FROM GLUCOMETER

This page provides a summary of

- Target A1C
- Target glucose range by time of day and in relationship to meals
- Demographic variables (i.e., type of diabetes, age, gender, pregnant)

CADS Results for 05/31/2012: Mixed CadsTest (DOB 01/17/1972)

Recommendations	Glucose Summary	Glucose Log Book	Glucose Graphs	Input Data
quest Facts				
Keys			Value	
TargetA1c			7.5	
DiabetesType			2	
Age			40	
Gender			M	
Pregnant			FALSE	
ucose Time Period Sett	3	r. 1 at		
Name	Start Time		Lower Limit	Upper Limit
	Start Time 09:00 PM	11:00 PM	95	150
Name	Start Time			
Name Bed Time (BT)	Start Time 09:00 PM	11:00 PM	95	150
Name Bed Time (BT) After Dinner (AD)	Start Time 09:00 PM 06:00 PM	11:00 PM 09:00 PM	95 95	150 250
Name Bed Time (BT) After Dinner (AD) All Day (AA)	Start Time 09:00 PM 06:00 PM 12:00 AM	11:00 PM 09:00 PM 12:00 AM	95 95 80	150 250 120
Name Bed Time (BT) After Dinner (AD) All Day (AA) Before Breakfast (BB)	Start Time 09:00 PM 06:00 PM 12:00 AM 07:00 AM	11:00 PM 09:00 PM 12:00 AM 09:00 AM	95 95 80 95 95	150 250 120 170
Name Bed Time (BT) After Dinner (AD) All Day (AA) Before Breakfast (BB) After Lunch (AL)	Start Time 09:00 PM 06:00 PM 12:00 AM 07:00 AM 12:30 PM	11:00 PM 09:00 PM 12:00 AM 09:00 AM 03:00 PM	95 95 80 95 95 95	150 250 120 170 250
Name Bed Time (BT) After Dinner (AD) All Day (AA) Before Breakfast (BB) After Lunch (AL) Night (NT)	Start Time 09:00 PM 06:00 PM 12:00 AM 07:00 AM 12:30 PM 11:00 PM	11:00 PM 09:00 PM 12:00 AM 09:00 AM 03:00 PM 07:00 AM	95 95 80 95 95 95 95	150 250 120 170 250 150

Metformin 1000 mg Twice a day None No Acarbose 25 mg After dinner None No Name Date Result A1C 06/29/2010 9.2 ALT 06/29/2010 67 Creatinine 06/29/2010 9 Diagnoses Code Diagnosis Name 403.1 BENIGN HYPERTENSIVE KIDNEY DISEASE Past Medications Medication Name Rosigilitazone 05/24/2009 00:21:00 SMBG Raw Data Value 05/24/2009 00:23:00 174 05/24/2009 01:31:6:00 120 05/24/2009 01:31:6:00 120 05/24/2009 01:31:6:00 120 05/24/2009 01:31:6:00 120 05/26/2009 01:31:6:00 118 05/25/2009 13:38:00 118 05/25/2009 13:38:00 246 05/25/2009 14:38:00 246 05/25/2009 14:38:00 246 05/25/2009 14:38:00 246 05/25/2009 14:38:00 246 05/25/20	8.8 M C	Dosage	Sig/Frequency	Side Effects	Stop Medication	
Name Date Result A1C 06/29/2010 9.2 ALT 06/29/2010 67 Creatinine 06/29/2010 .9 Diagnoses Code Diagnosis Name 403.1 BENIGN HYPERTENSIVE KIDNEY DISEASE Past Medications Medication Name Rosiglitazone SMBG Raw Data Date Time Value 05/24/2009 00:21:00 91 05/24/2009 00:31:5:00 178 05/24/2009 00:57:00 174 05/24/2009 00:57:00 217 05/25/2009 00:33:00 174 05/25/2009 01:30:00 118 05/25/2009 01:30:00 118 05/25/2009 11:38:00 246 05/25/2009 12:00 246	Ivietformin	1000 mg	Twice a day	None	No	
Name Date Result A1C 06/29/2010 9.2 ALT 06/29/2010 67 Creatinine 06/29/2010 .9 Diagnoses 06/29/2010 .9 Code Diagnosis Name	Acarbose	25 mg	After dinner	None	No	
A1C 06/29/2010 9.2 ALT 06/29/2010 67 Creatinine 06/29/2010 .9	abs					
ALT 06/29/2010 67 Creatinine 06/29/2010 .9 Diagnoses Code Diagnosis Name 403.1 BENIGN HYPERTENSIVE KIDNEY DISEASE					Result	
Diagnoses Od/29/2010 .9 Diagnoses Diagnosis Name Od/29/2010 .9 403.1 DENIGN HYPERTENSIVE KIDNEY DISEASE Past Medications Medication Name Resiglitazone Name Na	A1C		06/29/2010		9.2	
Diagnoses Code Diagnosis Name 403.1 BENIGN HYPERTENSIVE KIDNEY DISEASE Past Medications Medication Name Rosiglitazone SMBG Raw Data Date Time Value 05/24/2009 00:21:00 91 05/24/2009 01:31:00 178 05/24/2009 13:16:00 120 05/24/2009 13:16:00 120 05/24/2009 13:16:00 120 05/24/2009 13:36:00 174 05/24/2009 13:36:00 174 05/25/2009 06:57:00 217 05/25/2009 08:34:00 145 05/25/2009 13:08:00 118 05/25/2009 13:08:00 246 05/25/2009 20:45:00 95	ALT		06/29/2010		67	
Code Diagnosis Name 403.1 BENIGN HYPERTENSIVE KIDNEY DISEASE Past Medications Medication Name Rosiglitazone BENIGN HYPERTENSIVE KIDNEY DISEASE SMBG Raw Data Value 05/24/2009 00:21:00 91 05/24/2009 01:316:00 178 05/24/2009 13:16:00 120 05/24/2009 13:16:00 120 05/24/2009 19:19:00 149 05/24/2009 23:36:00 174 05/24/2009 00:57:00 217 05/25/2009 00:57:00 217 05/25/2009 01:30:00 148 05/25/2009 01:30:00 118 05/25/2009 13:08:00 118 05/25/2009 20:45:00 95	Creatinine		06/29/2010		.9	
Code Diagnosis Name 403.1 BENIGN HYPERTENSIVE KIDNEY DISEASE Past Medications Medication Name Rosiglitazone Rosiglitazone SMBG Raw Data Value 05/24/2009 00:21:00 94 05/24/2009 01:31:6:0 120 05/24/2009 13:16:0 120 05/24/2009 19:19:00 149 05/24/2009 23:36:00 174 05/24/2009 00:57:00 217 05/25/2009 00:57:00 217 05/25/2009 01:30:00 145 05/25/2009 01:30:00 118 05/25/2009 14:38:00 246 05/25/2009 20:45:00 95	agnoses					
Value Value Os/24/2009 00:21:00 91 O5/24/2009 00:21:00 91 O5/24/2009 07:35:00 178 O5/24/2009 13:15:00 120 O5/24/2009 13:15:00 120 O5/24/2009 13:15:00 120 O5/24/2009 13:15:00 120 O5/24/2009 13:16:00 149 List of each BG O5/25/2009 00:57:00 217 value by Date O5/25/2009 13:08:00 118 and Time. O5/25/2009 20:45:00 95	Code Diagnosis					
Medication Name Rosiglitazone SMBG Raw Data Date Time Value 05/24/2009 00:21:00 91 05/24/2009 07:35:00 178 05/24/2009 13:15:00 120 05/24/2009 13:15:00 149 05/24/2009 19:19:00 149 05/24/2009 00:57:00 217 05/25/2009 00:57:00 217 05/25/2009 01:30:00 145 05/25/2009 13:08:00 118 05/25/2009 13:08:00 246 05/25/2009 20:45:00 95	403.1 BENIGN H	YPERTENSIVE KIDN	EY DISEASE			
05/24/2009 23:35:00 174 List of each BG 05/25/2009 00:37:00 217 value by Date 05/25/2009 03:34:00 145 value by Date 05/25/2009 13:08:00 118 ob/25/2009 05/25/2009 14:38:00 246 ob/25/2009 05/25/2009 20:45:00 95 ob/25/2009						
05/25/2009 00:57:00 217 05/25/2009 08:34:00 145 05/25/2009 13:08:00 118 05/25/2009 14:38:00 246 05/25/2009 20:45:00 95	Date Time 05/24/2009 00:21:00 05/24/2009 07:35:00	91 178 120				
05/25/2009 08:34:00 145 value by Date 05/25/2009 13:08:00 118 and Time. 05/25/2009 20:45:00 95 95	Date Time 05/24/2009 00:21:00 05/24/2009 07:35:00 05/24/2009 13:15:00 05/24/2009 19:19:00	91 178 120 149		ist of each BG		
05/25/2009 13:08:00 118 05/25/2009 14:38:00 246 05/25/2009 20:45:00 95	Date Time 05/24/2009 00:21:00 05/24/2009 07:35:00 05/24/2009 13:15:00 05/24/2009 13:15:00 05/24/2009 13:15:00 05/24/2009 23:35:00	91 178 120 149 174		st of each BG		
05/25/2009 14:38:00 246 and Time. 05/25/2009 20:45:00 95	Date Time 05/24/2009 00:21:00 05/24/2009 07:35:00 05/24/2009 13:15:00 05/24/2009 13:15:00 05/24/2009 19:19:00 05/24/2009 23:35:00 05/25/2009 00:57:00	91 178 120 149 174 217				
05/25/2009 14:38:00 246 05/25/2009 20:45:00 95	Date Time 05/24/2009 00:21:00 05/24/2009 07:35:00 05/24/2009 13:15:00 05/24/2009 19:19:00 05/24/2009 23:35:00 05/25/2009 00:57:00 05/25/2009 08:34:00	91 178 120 149 174 217 145				
	Date Time 05/24/2009 00:21:00 05/24/2009 07:35:00 05/24/2009 13:15:00 05/24/2009 13:15:00 05/24/2009 13:15:00 05/24/2009 23:35:00 05/25/2009 00:700 05/25/2009 08:34:00 05/25/2009 13:08:00	91 178 120 149 174 217 145 118	Va	alue by Date		
	Date Time 05/24/2009 00:21:00 05/24/2009 07:35:00 05/24/2009 13:15:00 05/24/2009 13:15:00 05/24/2009 13:15:00 05/24/2009 23:35:00 05/25/2009 00:57:00 05/25/2009 00:34:00 05/25/2009 13:08:00 05/25/2009 14:38:00	91 178 120 149 174 217 145 118 246	Va	alue by Date		
	Date Time 05/24/2009 00:21:00 05/24/2009 07:35:00 05/24/2009 13:15:00 05/24/2009 13:15:00 05/24/2009 13:15:00 05/24/2009 13:15:00 05/24/2009 03:35:00 05/24/2009 00:57:00 05/25/2009 00:34:00 05/25/2009 13:08:00 05/25/2009 14:38:00 05/25/2009 20:45:00	91 178 120 149 174 217 145 118 246 95	Va	alue by Date		
	Date Time 05/24/2009 00:21:00 05/24/2009 07:35:00 05/24/2009 13:15:00 05/24/2009 13:15:00 05/24/2009 23:35:00 05/24/2009 03:35:00 05/25/2009 08:34:00 05/25/2009 08:34:00 05/25/2009 14:38:00 05/25/2009 20:45:00 05/25/2009 90:38:00	91 178 120 149 174 217 145 118 246 95 121	Va	alue by Date		
05/27/2009 07:55:00 161 05/27/2009 08:41:00 212	Date Time 05/24/2009 00:21:00 05/24/2009 07:35:00 05/24/2009 13:15:00 05/24/2009 13:15:00 05/24/2009 13:15:00 05/24/2009 23:35:00 05/25/2009 06:7:00 05/25/2009 08:34:00 05/25/2009 13:08:00 05/25/2009 14:38:00 05/25/2009 20:45:00 05/26/2009 91:38:00 05/26/2009 12:45:00	91 178 120 149 174 217 145 118 246 95 121 136	Va	alue by Date		

26

Summary Tab

Recommendations	Gluc	ose Summar	y Gluc	ose Log E	Book	Glucose	Graphs	Input Data	
Analysis Date Range	Fre	quency of Mo	nitoring	Day	s with Da	ta	Number of	Data Points	
05/01/2009 - 12/31/2009	2 Te	ests/Day		218			595		
	All Dav	Before Breakfast	After Breakfast	Before Lunch	After Lunch	Before Dinner		Bed Time	Nigh
Targets	80 - 120	95 - 170	95 - 250	95 - 170	95 - 250	95 - 170		95 - 150	95 - 15
Problem	High	High		Low	Low		Low	High	Hig
Number of Values	595	117	37	53	80	7	156	26	11
Average	154	161	168	130	163	151	135	181	16
Standard Deviation	48	40	48	43	69	48	37	50	4
Range	33 - 354	81 - 293	87 - 296	53 - 316	60 - 354	99 - 247	40 - 245	95 - 315	33 - 27
Percent Low	8.9	3.4	2.7	17.0	13.8	0.0	15.4	0.0	3.
Percent High	25.7	39.3	8.1	3.8	13.8	14.3	0.0	69.2	60

Glucose Summary identifies

- Analysis Date Range
- Frequency of Monitoring
- Days with Data
- Number of Data Points
- Target BG range for each time range
- Percentage of low BG values by time of day
- Percentage of target BG values by time of day
- Percentage of high BG values

Problem areas are noted in "Percent low" and "Percent high" by the color change (red or blue). For example, this person has a high percentage of low BG readings before and after lunch, while bedtime and night readings run high. Glucose Graphs

- To see the glucose graphs – click the "glucose graphs" tab on the screen above (between Glucose Log Book and Input Data)



Remember: the colors mean the same things on these graphs that they did previously:

red = high blue = low green = target range



Glucose Values by Time Period Percent 100 ---90 80 70 60 50 40 30 20 10 BB BL AL BD AD BT AA AB NT Low 📕 In Target Range 📕 High

The abbreviations on the lower axis of the graphs correpond to the time chunks on previous screens: AA: All Day BB: before breakfast AB: after breakfast BL: before lunch AL: after lunch BD: before dinner AD: after dinner BT: Bedtime NT: Nighttime

There are a lot of options for types of graphs that CADS can produce. Here are a few more examples:



When the glucose data is grouped by Time Period, horizontal lines are shown for the median $(50^{\text{th}} \text{ percentile})$ (longer lines), and for the 25^{th} and 75^{th} percentiles (shorter lines). In the example shown, slightly more than 50% of the night-time glucoses are within target and slightly less than 50% are higher than target.

Data points are still color coded red (high), green (target) and blue (low) with the ranges that were set in CADS during setup and identification of the ideal A1c for this specific patient.

Remember that all these ranges can be set by the provider, so that the ranges are specific to the individual circumstances of each of the patients. These values can be adjusted in Analysis Setup at any point while using the program.



30



Pie Charts can be created as another way to display the patterns of BG over time and by meals.



BIBLIOGRAPHY

Algorithms and Guidelines AACE/ACE ADA VA/DOD CADS system Analysis of SMBG data

1. AACE Algorithm

https://www.aace.com/sites/default/files/GlycemicControlAlgorithm.pdf

https://www.aace.com/sites/default/files/GlycemicControlAlgorithmPPT.pdf

https://www.aace.com/sites/default/files/Diabetes_Algorithm_120909_PC_final_animated.ptt

2. ADA/EASD

http://care.diabetesjournals.org/content/29/8/1963.full.pdf+html

3. VA/DOD guideline short version:

http://www.healthquality.va.gov/diabetes/DM2010_SUM-v4.pdf

4. VA/DOD guideline long version:

http://www.healthquality.va.gov/diabetes/DM2010_FUL-v4e.pdf

5. AACE guideline 2011

https://www.aace.com/sites/default/files/DMGuidelinesCCP.pdf

CADS:

Rodbard D, Vigersky RA. Design of a Decision Support System to Help Clinicians Manage Glycemia in Patients with Type 2 Diabetes Mellitus. J Diab Sci Tech. 2011 (Mar); 5 (2): 402-411 and on-line Appendix.

Analysis and Interpretation of SMBG Data:

Rodbard, D. Optimizing Display, Analysis, Interpretation and Utility of Self-Monitoring of Blood Glucose (SMBG) Data for Management of Patients with Diabetes. Journal of Diabetes Science and Technology, 1 (1): 62 - 71, 2007.

CURRENT ISSUES WITH TZDs

GSK re Rosiglitazone (Avandia), with Risk elimination program:

http://www.gsk.com/media/pressreleases/2011/2011_pressrelease_10024.htm

FDA re withdrawal of Pioglitazone (Actos) in France and Germany:

http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm

http://care.diabetesjournals.org/content/34/4/916.long

Trouble Report

Note: This form can be submitted anonymously without the name of the provider, or patient, or both.

- 1. Name of Clinician: (optional)
- 2. Date:
- 3. Facility: WRNMMC, WHASC, UH
- 4. Patient Identifier: (optional)
- 5. Nature of the Problem
- 6. Severity of the Problem
- 7. Is there any risk to the patient, or likely to be any risk to any other patient as a result of this problem?

Directions for using CDMP for Hawaii for the CADS Study

TO BEGIN

Welcome to the Comprehensive Diabetes Management Program Hawaii CADS
Please enter your Username and Password to continue
Username: Password: Login Forgot Password? To login using a digital certificate, please close the browser and try
again.

Enter the Username and Password you have been assigned to login to the Comprehensive Diabetes Management Program Hawaii CADS Website. The link for the website is https://prod.estenda.com/hawaii/cads/cdmp/

ter Add Patient	Studies							
close all	Manager Home							
er	Manager Home						_	
its iearch								
ubject Stu					Status: All	*		
	y Name	Planned Start	Planned End	Enrollment	Search			
	Provider Patient Pre-provider	07/01/2011	10/18/2012	2 of 12 enrolled	Search Subjects			
Rand	omization	10/18/2011	10/18/2012	8 of 228 enrolled	Search Subjects			
CAD	Patient Randomized	10/18/2011	10/18/2012	0 of 228 enrolled	Search Subjects			

In order to begin entering data, you will need to create a subject.

open all close all							
Study Manager	Study Manager Home						
To-Do Lists						_	
Subject Search	Studies				Status: All		
Create Subject	Study Name	Planned Start	Planned End	Enrollment	Status: All 🗸		
Study Config	CADS Provider	07/01/2011	10/18/2012	2 of 12 enrolled	Search Subjects		
Letters	CADS Patient Pre-provider Randomization	10/18/2011	10/18/2012	8 of 228 enrolled	Search Subjects		
	CADS Patient Randomized	10/18/2011	10/18/2012	0 of 228 enrolled	Search Subjects		

Click the "Create Subject" button on the right hand side of the screen.

Comprehensiv Status Center Add F		nagement Program	M Search User Pref Admin Help Log Out	^
open all close all	Create New S	ubject		
Study Manager To-Do Lists			Save Cancel	
-Subject Search -Create Subject -Study Config -Letters	Subject Info	Salutation * Quick Search Name	First MI Last Suffix Date of Birth (mm/dd/yyyy) Gender Y	
u-Letters		Address	Home Phone (888)	
	Contact Info	City	Cel Phone (808)	
		State Country	Zip Code Email Address	
	Additional Data	Pregnant Subject Notes	Subject Status Ethnicity	
	* = Required Field		Save Cancel	
				~
			😜 Internet 🔍 100%	•

Now type in the information you want entered into CDMP for your subject. For now (when testing) make a "fake" patient – for this example I have used Donald Duck.

Status Center Add		nagement Progra	m	Se	arch User Pref Ad	lmin Help Log Ou		•
open all close all	Create New Su	ıbject					_	
Study Manager To-Do Lists					Save	Cancel		
─Subject Search ─Create Subject ─Study Config ⊡-Letters	Subject Info	Salutation * Quick Search Name	• First Donald DonaldDuck	MI Last Duck * Date of Birth 5/15/19	12 (mm/dd/yyyy)	Suffix * Gender M 💙		
±r⊥etters	Contact Info	Address City State Country	Zip Code United States	Home Phor Work Phor Cell Phor Email Addres	e (808)	x		
	Additional Data	Pregnant Subject Notes	Subject Status	▼ Ethni	ity	V		
	* = Required Field				Save	Cancel		-
Error on page.					1		😜 Internet	® 100% •

Click Save.

mprehensive Diabetes Management Program Center Add Patient Studies	Search User Pref Admin Help Log Out
n all close all O Successfully created new subject.	
lanager Do Lists <u>Subject Home - Donald Duck</u> ject Search	✓ Research
ate Subject Studies Targeted/Enrolled by Config Study Study Status	Add Study Subject Status Arm Enroll. Date
ect No studies found. ers	
Appointments Date & Time Notes No appointments found.	Timeframe: All Study: Y Provider Study Name
	Sinternet

Now you want to add Donald Duck to the study. Click "Add Study."

CDMP - Add Study - Wi.	🗖 🗖 🔀
🙋 https://prod.estenda.com/hawaii/ca	ads/cdmp 🛩 🔒
Eligible Studies	•
CADS Patient Pre-provider Randomization	Add
CADS Patient Randomized	Add
CADS Provider	Add
	Cancel
	Cancer
For Official Use Only	
Internet	🔍 100% 🔹 🚲

There are three studies available. If Donald Duck were a provider, you would Add the CADS Provider study. For this example, we are assuming Donald Duck is a patient, so we are adding him to the CADS Patient Pre-provider Randomization study. All patients will start with this study. After 19 patients have been recruited for a specific provider and all patients have completed the CADS Patient Pre-provider Randomization study, the patients will be enrolled in the CADS Patient Randomized study.

Comprehensiv			t Program		Search User Pref Admin	Help Log Out			
open all close all	Subject S	tudy Details ·	Donald Duc	k					
tudy Manager —To-Do Lists		Study: CADS Patie Randomiza	nt Pre-provider tion	Subject Status: New	Screener Passed: Not Completed]			
—Subject Search —Create Subject —Study Config	Enrollmer	nt Process In	formation			1			
-Study Config -Subject -Letters		ig Survey: CADS Pa ng Status: Not Start	ed						
			Launch Scree	ner					
	Activity								
	Type System	Date 10/27/2011	Status New	Description Study added by a user to this subject.	Action				
					Add New				
Done							😜 Internet	€ 100% ·	1

You need to screen the patient to make sure they are eligible for the study. For test purposes, all the answers on the Screener must be yes for CDMP to allow you to continue to enroll your fake patient in the study.

nttps://prod.estenda.com/nawaii/cads/survey/patient-survey-get-action.do	~
CADS Patient Screener	
CADS CHECKLIST	0
* 18 years of age or older	
O Yes	
O No C	la de la Maria 📜 de la la
	Next

In every survey question, you will enter an aswer and either push the "enter" key on your keyboard or click on the "next" box.

Survey - Complete Survey Webpage Dialog	×
https://prod.estenda.com/hawaii/cads/survey/patient-survey-get-action.do	~ 🔒
Complete Survey	?
CADS PATIENT SCREENER	
Thank you for taking this survey. You may use the Review Survey button to change your answers. You must press the Complete button to complete this survey.	
Review Survey Complete	
https://prod.estenda.com/hawaii/cads/survey/patient-survey-get-action.do	

When you are finished with the survey you can either click on "Review Survey" to check yoru answers or click on "Complete" to finish and save the data.

Comprehensiv Status Center Add			t Program		Search	User Pref Admin	Help Log Out		^			
open all close all	Subject St	udy Details -	Donald Duc	¢				_				
Study Manager To-Do Lists	S	tudy: CADS Patier Randomizati	nt Pre-provider ion	Subject Status: Eligible	Screener Passed: Y	es						
—Subject Search —Create Subject	Enrollment Process Information											
-Study Config ⊕-Subject ⊕-Study		Screening Survey Screening Status		reener								
⊞-Letters		Arm Name Subject Code	e: All Patients 💌									
		Questionnaire lo	i:									
	Verba	lly Consented										
	Activity L											
	Туре	Date	Status	Description		Actio	n					
	System	10/27/2011	Eligible	The subject passed the scr								
	System	10/27/2011	New	Study added by a user to th	nis subject.							
						Add New)					
									~			
Done	•							😝 Internet	• 100% •			

Donald Duck has passed the screener so you can consent him to participate in the study. You will have him sign the consent, enter his Subject Code and Questionnaire id based on yoru assigned values and then click on the button that says "verbally consented." Later in the process you will be uploading the signed consent form (during study visit 1).

Comprehensiv Status Center Add P		inagement Prog	gram		Search User Pref	Admin	Help Log Out			
open all close all	Subject Stud	y Details - Dona	ld Duck							
tudy Manager —To-Do Lists —Subject Search —Create Subject —Study Config	Study: CADS Patient Pre- provider Randomization Arm: All Patients Subject Code:		Subject Status: Verbally Consented Signed Informed Consent: No Questionnaire Code:		Screener Passed: Yes Enrollment Date:					
-Subject -Study	Arm Steps									
-Letters	1 Sta		Red Aler 11/03/2011	Completed	Action Update View Details	Finished 10/27/2011				
		it 1 isent gnancy Test Negative	11/03/2011	Not Scheduled Inactive Inactive	Schedule View Details					
	5 DTS 6 SF-	sa		Inactive						
	7 Der	nographic Form		Inactive						
	Activity Log Type	Date Sta	tuc	Description		Action				
	System	10/27/2011 Ver	ally Consented	The subject is eligible for the study and ve		Action				
		10/27/2011 Eligi 10/27/2011 Nev		The subject passed the screener question Study added by a user to this subject.	naire.					
					•	Add New				
								😜 Internet	Q 10	0.04

Schedule visit 1 for Donald Duck by clicking on the area that says "Schedule."

Comprehensiv Status Center Add	/e Diabetes Manaç Patient Studies	gement Program	Search User Pref Admin H	lelp Log Out	•
open all close all	Schedule Appoint	tment - Donald Duck			
Study Manager —To-Do Lists —Subject Search —Create Subject —Study Config ⊕-Subject ⊕-Study ⊕-Letters			~		
	Appointments Date & Time No appointments found.	Notes	Provider Study Name Schedule Cancel		~
Done				😜 Internet	🔍 100% 🔹 🛒

Enter the Appointmnet Date and Time for Visit 1.

open all close all Schedule Appointment - Donald Duck	
Study Manager Study Name: CADS Patient Pre-provider Rame Subject Search Arm Name: All Patients Study Config Step Name: Vial 1 Times Rescheduled: 0 P-Letters Appointment Date*: 10/29/2011 Appointment Wth: Laurie Location: Office	
Appointments Date & Time Notes No appointments found.	Provider Study Name

Press Schedule to enter the appointment into the system.

Status Center Add I	ve Diabetes Management P Patient Studies	rogram	Search User Pref Admin Help Log Out
open all close all	O Appointment scheduled succ	essfully.	
Study Manager To-Do Lists Subject Search	Subject Study Details - Do	onald Duck	
Create Subject Study Config	Study: CADS Patient Pre- provider Randomiz Arm: All Patients Subject Code:	ation Subject Status: Verbally Cons Signed Informed Consent: No Questionnaire Code:	ented Screener Passed: Yes Enrollment Date:
⊕-Study ⊞-Letters	Arm Steps		
	Step # Step Name Start	Red Alert Status Completed	Action Finished Update View Details 10/27/2011 Reschedule / Complete
	2 Visit 1 3 Consent 4 Pregnancy Test Negati	11/03/2011 Scheduled 10/29/201 Inactive ve Inactive	1 08:00 AM View Details
	5 DTSQ 6 SF-8	Inactive Inactive	
	7 Demographic Form	Inactive	
	Type Date System 10/27/2011	Status Description Verbally Consented The subject has been scheduled Verbally Consented The subject is eligible for the student is eligi	I for appointment Visit 1. dy and verbally agreed to join the study.
	System 10/27/2011	Eligible The subject is engine for the sub Eligible Study added by a user to this su	r questionnaire.
			(Add New)
Done			💽 Internet 🔍 100% 🔸

You can now continue the steps in Visit 1. Do this by pressing "Complete" and the other steps will open up and allow you to complete them.

	e Diabetes Managen	nent Program Search User Pref Admin Help Log Out
Status Center Add F	Patient Studies	
open all close all	Step Completion - D	onald Duck
Study Manager To-Do Lists Subject Search		CADS Patient Pre-provider Randomization All Patients
-Create Subject	Step Name:	Visit 1
-Study Config	Step Description:	
E-Subject	Appointment Date:	10/29/2011 08:00 AM
⊕-Subject ⊕-Study ⊕-Letters	Appointment Location:	Office
	Appointment With:	Laurie
	Appointment Details:	
	Date Completed*:	10/27/2011
	Notes:	
	Document Name:	
	Document:	Browse The max file size is 10,485,760 bytes (10 mb) The following are valid extension types: bxt, doc, pdf, xis, vsd, bmp, png, jpeg, jpg, jpe, jff, gif, dib,
		Complete Skip Cancel
Done		🔪 Internet 🕫 100% 🔹

Click complete.

all close all	Stan was e	uccessfully comp	lated							
	J step was s	uccessiony comp	neteu.							
nager										
	ibject Stud	ly Details - D	onald D	uck					_	
ct Search		CADS Patient Pre-								
e Subject	Study:	provider Randomi			Subject Status: Verbally Consented	Screener Pase	sed: Yes			
Config	Arm:	All Patients			rmed Consent: No	Enrollment D	ate:			
	Subject Code:			Ques	tionnaire Code:					
rs										
	Arm Steps									
5		tep Name	R	ed Aler		Action		Finished		
1		art			Completed	Update Vie		10/27/2011		
2		sit 1		1/03/2011	Completed	Update Vie		10/27/2011		
3		onsent		1/03/2011	Active	Complete				
4		egnancy Test Nega		1/03/2011	Active	Compose				
5		rsq =-8		1/03/2011	Active Active	Complete				
0		o emographic Form		1/03/2011	Active	Complete				
1	De	emographic Form	1	1/01/2011	Active	Complete	New Details			
	ctivity Log									
	уре	Date	Status		Description			Action		
	ystem	10/27/2011	Verbally Co		Step Visit 1 has been completed.					
S	ystem		Verbally Co	onsented	The subject has been scheduled for appointn	ent Visit 1.				
S	ystem		Verbally Co	onsented	The subject is eligible for the study and verba	lly agreed to join the	e study.			
S	ystem	10/27/2011	Eligible		The subject passed the screener questionnal	re.				
S	ystem	10/27/2011	New		Study added by a user to this subject.					
								Add New		
								Add New		

You are now going to upload the signed consent form. CLlick "Complete" in Step # 3 (Consent).

Comprehensiv Status Center Add	re Diabetes Managem Patient Studies	search User Pref Admin Help Log Out	^
open all close all	Step Completion - D	onald Duck	
Study Manager -To-Do Lists -Subject Sarch -Create Subject -Study Config D-Study Charles -Study Config D-Study Charles -Study Config D-Study Charles -Study Config D-Study Charles -Study Config D-Study -Study Config -Study Config D-Study -Study Config D-Study -Study -Study Config D-Study -Study -Study Config -Study	Study Name:	CADS Patient Pre-provider Randomization All Patients	
Done	<u> </u>	😜 Internet 🔍 100% 👻	×

You will click "Browse" and choose Donald Duck's signed Consent Form. Once that file name is in the Document: box you can complete this step.

Analysis Subject Study Details - Donald Duck Subject Study Config Subject Study: CaDS Patient Pre- growter Randomization Subject Study: CaDS Patient Pre- growter Randomization Subject Study Arm Steps Enrollment Date: 10/27/2011 Study: CaDS Patient Pre- growter Randomization Subject Study: CaDS Patient Pre- growter Randomization Subject Study: CaDS Patient Pre- growter Randomization Subject Code: Arm Steps Enrollment Date: 10/27/2011 Staff Consent Trins Step 3 Staff Consent Trins Step 3 Staff Consent Trins Step 3 Staff Consent Trins Step 4 Staff Consent Trins Step 5 Staff Consent Trins Step 6 Staff To Staff Step 1 Completed Update I (Yew Details 10/27/2011 Staff To Staff Step 1 Step 2 Complete Uriew Details 10/27/2011 Staff To Staff Step 1 Step Consented Trins Step 2 Completed System 10/27/2011 Verbally Co	us Center Ado en all close all		as successfully com	pleted								
Subject Study Subject Study Subject Study CADS Patient Pre- provider Randomization Arm: All Patients Subject Status: Enrolled Screener Passed: Yes subject Subject Code: Signed Informed Consent: Yes Enrollment Date: 10/27/2011 ubiget Subject Code: Subject Status: Enrolled Screener Passed: Yes subject Subject Code: Signed Informed Consent: Yes Enrollment Date: 10/27/2011 ubiget Stati Completed Update View Details 10/27/2011 2 Vist 1 11/03/2011 Completed Update View Details 10/27/2011 3 Consent 11/03/2011 Completed Update View Details 10/27/2011 4 Pregnanor Test Negative 11/03/2011 Active Completed Update View Details 10/27/2011 5 DTSQ 11/03/2011 Active Completed View Details 10/27/2011 6 Sr-4 11/03/2011 Active Completed View Details 5 7 Demographic Form 11/03/2011 Active Completed View Details 5 5 ystem 10/27/2011 <td< th=""><th></th><th>U step wa</th><th>is successfully com</th><th>ipieteu.</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></td<>		U step wa	is successfully com	ipieteu.								
reate Subject tudy Config ubject tudy Config ubject tudy etters		Subject S	tudy Details - I	Donald Duck								
Study Config Study: Trovider Randomization Subject Status: Enrolled Screener Passed: Yes ubject Arm: All Patients Signed Informed Consent: Yes Enrollment Date: 10/27/2011 ubject Code: Questionnaire Code: Arm: Steps Step * Step Name Red Alert Status Action 1 Stati Completed Update View Details 10/27/2011 Stati Completed Update View Details 10/27/2011 Stati Completed Update View Details 10/27/2011 Completed Update View Details 10/27/2011 2 Viet 1 11/03/2011 Completed Update View Details 3 Consent 11/03/2011 Active Completed View Details 4 Pregnancy Test Negative 11/03/2011 Active Complete View Details 6 SF-8 11/03/2011 Active Complete View Details 7 Ype Date Status Description Active System 10/27/2011 Step Consent has been completed. System System 10/27/2011 Verbally Consented Step Viet Nable approxemante S	ibject Search									-	-	
Arm: All Patients Signed Informed Consent: Yes Enrollment Date: 10/27/2011 udy contig Arm: Steps Consent: Yes Enrollment Date: 10/27/2011 Yetters Start Completed Update View Details 10/27/2011 2 Vat 1 11/03/2011 Completed Update View Details 10/27/2011 3 Consent 11/03/2011 Completed Update View Details 10/27/2011 4 Prepancy Test Negative 11/03/2011 Active Complete View Details 10/27/2011 4 Prepancy Test Negative 11/03/2011 Active Complete View Details 10/27/2011 5 DTSQ 11/03/2011 Active Complete View Details 10/27/2011 6 SF-3 11/03/2011 Active Complete View Details 10/27/2011 7 Demographic Form 11/01/2011 Active Complete View Details 10/27/2011 System 10/27/2011 Verbaily Consented The subject ased ased the subject ased the subject ased and the subject ased the	reate Subject	Stu			Subject Status:	Enrolled	Screener Pa	ssed: Yes				
Ubject subject Code: Questionnaire Code: udy tters Arm Steps Step # Step Name Red Alert Status Action 1 Stat Completed Update View Details 1027/2011 2 Valt 11/03/2011 Completed Update View Details 1027/2011 3 Consent 11/03/2011 Active Completed Update View Details 1027/2011 4 Pregnancy Test Negative 11/03/2011 Active Complete View Details 10/27/2011 5 DTSQ 11/03/2011 Active Complete View Details 10/27/2011 6 SF-8 11/03/2011 Active Complete View Details 0 7 Demographic Form 11/01/2011 Active Complete View Details Activity Log Type Date Status Description Action System 10/27/2011 Verabily Consented Step Consented View Details System 10/27/2011 Verabily Consented The subject as eligible for the subject opinithent Vist 1. System 10/27/2011 Verabily Consented The subject as eligible for the subya and verabily agrees to join the study. <t< th=""><th>udy Config</th><th></th><th></th><th></th><th>Unformed Consent</th><th>Ver</th><th>Enrollment</th><th>Date: 10/27/20</th><th>11</th><th></th><th></th><th></th></t<>	udy Config				Unformed Consent	Ver	Enrollment	Date: 10/27/20	11			
Arm Steps Step # Step Name Red Alert Status Action Finished 1 Stat Completed Update View Details 1027/2011 2 Val 1 11032011 Completed Update View Details 1027/2011 3 Consent 11/032011 Completed Update View Details 1027/2011 4 Pregnancy Test Negative 11/032011 Active Complete View Details 1027/2011 5 DTSO 11/032011 Active Complete View Details 1027/2011 6 SF-8 11/032011 Active Complete View Details Towe Details 7 Demographic Form 11/01/2011 Active Complete View Details System 10/27/2011 Enroled Step Consent As been completed. View Details System 10/27/2011 Verbally Consented The subject is eligible for the subject is software System 10/27/2011 Verbally Consented The subject is eligible for the subject is software System 10/27/2011 Verbally Consented The subject is	ıbject						Enrollinein	Dute. 10/21/20				
Arm Steps Step # Step # Step # Step # Status Completed Update View Details 10027/2011 2 Vist 1 11/03/2011 Completed Update View Details 10027/2011 3 Consent 11/03/2011 Completed Update View Details 10/27/2011 4 Pregnancy Test Negative 11/03/2011 Active Complete View Details 10/27/2011 5 DTSQ 11/03/2011 Active Complete View Details 10/27/2011 6 SF-8 11/03/2011 Active Complete View Details 5 7 Demographic Form 11/01/2011 Active Complete View Details 5 7 Demographic Form 11/01/2011 Active Complete View Details 5 8 9/394m 10/27/2011 Erroled Step Consented Step Consented Step View Details 5 9/394m 10/27/2011 Verbaily Consented The subject is eligible for the study. System 10/27/2011 Verbaily Consented The subject astep Con	idy											
Step # Step Name Red Alert Status Action Finished 1 Start Completed Update View Details 1027/2011 2 Viak 1 11/03/2011 Completed Update View Details 1027/2011 3 Consent 11/03/2011 Completed Update View Details 1027/2011 4 Pregnancy Test Negative 11/03/2011 Active Complete View Details 1027/2011 5 OTSQ 11/03/2011 Active Complete View Details 1027/2011 5 OTSQ 11/03/2011 Active Complete View Details 6 SF-8 11/03/2011 Active Complete View Details 7 Demographic Form 11/01/2011 Active Complete View Details 7 Date Status Description Action System 10/27/2011 Enrolled Step Consent has been completed. System System 10/27/2011 Verbaily Consented The subject has been completed. System 10/27/2011 Verbaily Consented The subject has been completed. System 10/27/2011 Verbaily Consented The subject has been completed.	tters											
1 Start Completed Update View Details 10/27/2011 2 Vait 1 11/03/2011 Completed Update View Details 10/27/2011 3 Consent 11/03/2011 Active Completed Update View Details 10/27/2011 4 Pregnancy Test Negative 11/03/2011 Active Complete View Details 10/27/2011 5 DTSQ 11/03/2011 Active Complete View Details 6 SF-8 11/03/2011 Active Complete View Details 7 Demographic Form 11/01/2011 Active Complete View Details View		Arm Step)5									
1 Start Completed Update View Details 1027/2011 2 Vast 1 11/03/2011 Completed Update View Details 1027/2011 3 Consent 11/03/2011 Completed Update View Details 10/27/2011 4 Pregnancy Test Negative 11/03/2011 Active Complete View Details 10/27/2011 5 DTSQ 11/03/2011 Active Complete View Details 10/27/2011 6 SF-8 11/03/2011 Active Complete View Details 7 Demographic Form 11/01/2011 Active Complete View Details Ype Date Status Description Action System 10/27/2011 Enrolled Step Consented Step Consented Step Consented Step Consented Ins subject acompleted. System 10/27/2011 Verbaily Consented The subject has been completed. System 10/27/2011 Verbaily Consented The subject has been completed. System 10/27/2011 Verbaily Consented The subject has been scheduled for appointment Vist 1. System 10/27/2011 Eligible The subject has scheavier questionnaire. System <				Red	Alert Stat	us	Action		Finished			
3 Consent 11/03/2011 Completed Update View Details 10/27/2011 4 Pregnancy Test Negative 11/03/2011 Active Complete View Details 5 DTSQ 11/03/2011 Active Complete View Details 6 SF-8 11/03/2011 Active Complete View Details 7 Demographic Form 11/01/2011 Active Complete View Details Activity Log Type Date Status Description Action System 10/27/2011 Enrolled Step Consented Step Consented Step Consented System 10/27/2011 Verbally Consented The subject as eligible for the study. System 10/27/2011 Eligible System 10/27/2011 Verbally Consented The subject as eligible for the study. System System 10/27/2011 Eligible The subject as eligible for the study. System 10/27/2011 Eligible The subject asset day and verbally agrees to join the study. System 10/27/2011 Eligible The subject asset day and verbally agrees to join the study. System 10/27/2011 New Study added by a user to this subject.		1	Start									
4 Preparacy Test Negative 11/03/2011 Active Complete View Details 5 DTSQ TV03/2011 Active Complete View Details 6 SF-3 11/03/2011 Active Complete View Details 7 Demographic Form 11/01/2011 Active Complete View Details Activity Log Type Date Status Description Action System 10/27/2011 Vierbally Consented Step Consented The subject is eligible for the study. System 10/27/2011 Verbally Consented The subject is eligible for the study. System 10/27/2011 Verbally Consented The subject is eligible for the study. System 10/27/2011 Verbally Consented The subject is eligible for the study. System 10/27/2011 Verbally Consented The subject is eligible for the study. System 10/27/2011 Eligible The subject is eligible for the study. System 10/27/2011 Eligible The subject is eligible for the study. System 10/27/2011 New Study added by a user to this subject.												
5 DTSQ 11/03/2011 Active Complete View Details 6 SF-8 11/03/2011 Active Complete View Details 7 Demographic Form 11/01/2011 Active Complete View Details Activity Log Yrpe Date Status Description Action System 10/27/2011 Enrolled Step Consent has been completed. System 10/27/2011 Verbally Consented The subject has been completed. System 10/27/2011 Verbally Consented The subject has been completed. System 10/27/2011 Verbally Consented The subject has been completed. System 10/27/2011 Verbally Consented The subject has been completed. System 10/27/2011 Verbally Consented The subject has creater questionnaire. System 10/27/2011 Eligible The subject has creater questionnaire. System 10/27/2011 Eligible The subject has been completed. System 10/27/2011 Eligible The subject has creater questionnaire. System System 10/27/2011 Eligible The subject hasouther									10/27/2011			
6 SF-8 11/03/2011 Active Complete View Details 7 Demographic Form 11/01/2011 Active Complete View Details Activity Log Type Date Status Description Action System 10/27/2011 Enrolled Step Consent has been completed. System 10/27/2011 Verbaily Consented The subject has been completed. System 10/27/2011 Verbaily Consented The subject has been completed. System 10/27/2011 Verbaily Consented The subject has been completed. System 10/27/2011 Verbaily Consented The subject has been completed. System 10/27/2011 Verbaily Consented The subject has been completed. System 10/27/2011 Verbaily Consented The subject has been completed. System 10/27/2011 Verbaily Consented The subject has been completed. System 10/27/2011 Eighble The subject asset of and verbaily agreed to join the study. System 10/27/2011 New Study added by a user to this subject.												
Type Date Status Description Action System 10/27/2011 Enrolled Step Consent has been completed. System System 10/27/2011 Verbally Consented Step Visit 1 has been completed. System System 10/27/2011 Verbally Consented Step Consent has been completed. System 10/27/2011 Verbally Consented The subject has been scheduled for appointment Visit 1. System 10/27/2011 Verbally Consented The subject for the study and verbally agreed to join the study. System 10/27/2011 Eligible The subject beside to scheduled for appointment. System 10/27/2011 Eligible The subject set beside has creener questionnaire. System 10/27/2011 New Study added by a user to this subject.		-										
Activity Log Date Status Description Action System 10/27/2011 Enrolled Step Consent has been completed. Step Visit 1 has been completed. System 10/27/2011 Verbally Consented Step Visit 1 has been achieved for appointment Visit 1. System 10/27/2011 Verbally Consented The subject has been achieved for appointment Visit 1. System 10/27/2011 Verbally Consented The subject is eligible for the study and verbally agreed to join the study. System 10/27/2011 Eligible The subject is set whet active and verbally agreed to join the study. System 10/27/2011 Eligible The subject is set whet active active and verbally agreed to join the study. System 10/27/2011 Eligible The subject is active a												
Type Date Status Description Action System 10/27/2011 Enroled Step Consent has been completed. Enroled System 10/27/2011 Verbally Consented Step Usit 1 has been completed. System 10/27/2011 Verbally Consented The subject has been scheduled for appointment Vist 1. System 10/27/2011 Verbally Consented The subject has been scheduled for appointment Vist 1. System 10/27/2011 Verbally Consented The subject has been scheduled for appointment Vist 1. System 10/27/2011 Verbally Consented The subject has extended for appointment Vist 1. System 10/27/2011 Verbally Consented The subject has extender questionnaire. System 10/27/2011 Eligible The subject has extender questionnaire. System 10/27/2011 New Study added by a user to this subject.		7	Demographic Form	11/01/	2011 Active	•	Complete	View Details				
Type Date Status Description Action System 10/27/2011 Step Consent has been completed. Step Consent has been completed. System 10/27/2011 Verbally Consented Step Visit 1 has been completed. System 10/27/2011 Verbally Consented The subject has been completed. System 10/27/2011 Verbally Consented The subject has been scheduled for appointment Visit 1. System 10/27/2011 Verbally Consented The subject for the study and verbally agreed to join the study. System 10/27/2011 Eligible The subject has scheduled for appointment. System 10/27/2011 Eligible The subject has completed. System 10/27/2011 New Study added by a user to this subject.								•				
System 10/27/2011 Enrolled Step Consent has been completed. System 10/27/2011 Verbally Consented Step Visit 1 has been completed. System 10/27/2011 Verbally Consented The subject has been acheduled for appointment Visit 1. System 10/27/2011 Verbally Consented The subject is eligible for the study and verbally agreed to join the study. System 10/27/2011 Eligible The subject is eligible for the study and verbally agreed to join the study. System 10/27/2011 Eligible The subject asset the screener questionnaire. System 10/27/2011 New Study added by a user to this subject.										_		
System 10/27/2011 Verbally Consented Step Visit 1 has been completed. System 10/27/2011 Verbally Consented The subject has been acheduled for appointment Visit 1. System 10/27/2011 Verbally Consented The subject has been acheduled for appointment Visit 1. System 10/27/2011 Verbally Consented The subject has ediplied for the study and verbally agreed to join the study. System 10/27/2011 Eligible The subject has ediplied for the screener questionnaire. System 10/27/2011 New Study added by a user to this subject.									Action	1		
System 10/27/2011 Verbally Consented The subject has been scheduled for appointment Vist 1. System 10/27/2011 Verbally Consented The subject is eligible for the study and verbally agreed to join the study. System 10/27/2011 Eligible The subject assed the screener questionnaire. System 10/27/2011 Eligible The subject assed the screener questionnaire.		System		Enrolled								
System 10/27/2011 Verbally Consented The subject is eligible for the study and verbally agreed to join the study. System 10/27/2011 Eligible The subject passed the screener questionnaire. System 10/27/2011 New Study added by a user to this subject.		System	10/27/2011	Verbally Conse	nted Step Visit 1 has	been completed.						
System 10/27/2011 Eligible The subject passed the screener questionnaire. System 10/27/2011 New Study added by a user to this subject.		System	10/27/2011	Verbally Conse	nted The subject has	been scheduled for appointmen	nt Visit 1.					
System 10/27/2011 New Study added by a user to this subject.		System	10/27/2011	Verbally Conse	nted The subject is el	gible for the study and verbally	agreed to join	the study.				
System 10/27/2011 New Study added by a user to this subject.		System	10/27/2011	Eligible	The subject pas	sed the screener questionnaire.						
		System	10/27/2011	New	Study added by	a user to this subject.						
Add New												
									Add New			

Continue to complete the Arm Steps for this study. Next is the pregnancy test.

Comprehensiv	re Diabetes Managem Patient Studies	Search User Pref Admin Help Log Out	^
open all close all	Step Completion - D	onald Duck	
Study Manager -To-Do Lists -Subject Search -Graets Subject -Study Config D-Subject D-Subject D-Study D-Letters	Arm Name:	Pregnancy Test Negative I027/2011 Pregnancy Test Negative Confirmed by Lab: 10/24/2011 Decove. The max file size is 10,455,760 bytes (10 mb) The following are valid extension types: bt, doc. pdf, xis, ved, bmo, png, jpg, jpg, jpf, gif, dib. Complete Skip Cancel	
		😜 Internet 🔍 100% 👻	:

Type in the notes section information about the pregnancy test (it must be negative). In addition you can upload the test results in the same way you uploaded the signed consent form.

II close all	Subject	Study Details - [Donald Duck					
nager Lists t Search		CADS Patient Pre provider Random Arm: All Patients Code:	ization Signed Info	Subject Status: Enrolled ormed Consent: Yes tionnaire Code:	Screener Passed: Yes Enrollment Date: 10/27/20	011		
: Subject Config :t	Arm Ste		4000					
s	Step #	Step Name	Red Aler		Action	Finished		
s	1	Start		Completed	Update View Details	10/27/2011		
	2	Visit 1	11/03/2011	Completed	Update View Details	10/27/2011		
	3	Consent Pregnancy Test Nega	11/03/2011 ative 11/03/2011	Completed Completed	Update View Details Update View Details	10/27/2011 10/27/2011		
	5	DTSQ	11/03/2011	Active	Complete View Details			
	6	SF-8	11/03/2011	Active	Complete View Details			
	7	Demographic Form	11/01/2011	Active	Complete View Details			
	Activity							
	Туре	Date 10/27/2011	Status Enrolled	Description		Action		
	System			Step Pregnancy Test Negative has been c	impiered.			
	System	10/27/2011	Enrolled	Step Consent has been completed.				
	System	10/27/2011		Step Visit 1 has been completed.				
	System	10/27/2011		The subject has been scheduled for appoi				
	System	10/27/2011		The subject is eligible for the study and ve				
	System	10/27/2011	Eligible	The subject passed the screener question	naire.			
	System	10/27/2011	New	Study added by a user to this subject.				
					(Add New		

Now you will complete the DTSQ for the patient.

Status Center Add	/e Diabetes Managem Patient Studies	nent Program Search User Pref Admin Help Log Out
open all close all	Step Completion - D	onald Duck
Study Manager -To-Do Lists -Subject Search -Greate Subject -Study Config -Study Config -Lefters	Study Name: Arm Name: Step Name: Step Description: Survey Name: Survey Status:	CADS Patient Pre-provider Randomization All Patients DTSQ DTSQ
Done		🖌 🚱 Internet 😤 100% 🔹 💥

Launch the DTSQ by clicking "Launch Survey"

Comprehensiv	ve Diabetes Managem	nent Program Search User Pref Admin Help Log Out	ā
Status Center Add			
open all close all	Step Completion - D	onald Duck	
open all close all Study Manager —To Do Lists —Subject Search —Create Subject —Study Config @-Subject @-Study @-Letters	Study Name: Arm Name: Step Name: Step Description: Survey Name:	CADS Patient Pre-provider Randomization All Patients DTSQ DTSQ Complete - View Survey	
		Complete Skip Cancel	
		😜 Internet 🔍 100% 👻	

Once the survey is completed click Complete.

Comprehensiv			Program		Search User Pref	Admin Help	Log Out		^
open all close all	O Step wa	as successfully comp	leted.						
Study Manager To-Do Lists Subject Search	Subject S	tudy Details - D	onald Duck						
-Create Subject -Study Config ⊕-Subject		udy: CADS Patient Pre- provider Randomiz Arm: All Patients	zation Signed Info	Subject Status: Enrolled rmed Consent: Yes tionnaire Code:	Screener Passed: Yes Enrollment Date: 10/27/201	11			
E Study E Letters	Arm Ste		QUES						
	Step # 1 2 3 4 5 6 7 Activity Type	Step Name Start Visit 1 Consent Pregnancy Test Negat OTSQ SF-8 Demographic Form Log Date	Red Aler 11/03/2011 11/03/2011 11/03/2011 11/03/2011 11/03/2011 11/03/2011 11/03/2011 Status	t Status Completed Completed Completed Completed Active Active Active Description	Action Update View Details Update View Details Update View Details Update View Details Update View Details Complete View Details Complete View Details	Finished 10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011			
	System System System System System System System	10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011	Verbally Consented	Step DTSQ has been completed. Step Pregnancy Test Negative has beer Step Consent has been completed. Step Visit 1 has been completed. The subject has been scheduled for an The subject adigible for the study and The subject passed the screener quest Study added by a user to this subject.	opointment Visit 1. I verbally agreed to join the study. tionnaire.				
Done						Add New	e	Internet	💌 🔍 100% 🔹 🛒

Now you will complete the SF-8.

					-					
Comprehensi	ve Diabetes Mana	gement Progra	m		Sea	arch User Pref	i Admin I	lelp Log Out		
tus Center Add	Patient Studies									
								_		
open all close all	O Step was succes	ssfully completed.								
		sonary completed.								
ly Manager										
o-Do Lists	Subject Study Do	etails - Donald	Duck							
ubject Search										
reate Subject		S Patient Pre-	5	Subject Status: Enrolled	Screener	Passed: Yes				
tudy Config	r prov	vider Randomization		· ·						
ubject	Arm: AII P Subject Code:	atients		med Consent: Yes onnaire Code:	Enrolime	nt Date: 10/27/20	11			
udy	Subject Code:		Quesu	onnaire code:						
etters										
ellers				we been completed. Click the button below to						
			this study and	I to allow the subject to enroll in other studies.						
				Complete						
				>						
	Arm Steps									
	Step # Step N	Jamo	Red Alert	Status	Action		Finished			
	1 Step # Step I	vanie	Red Alert	Completed		View Details	10/27/2011			
	2 Visit 1		11/03/2011	Completed		View Details	10/27/2011			
	3 Consent		11/03/2011	Completed	Update	View Details	10/27/2011			
	4 Pregnan	icy Test Negative	11/03/2011	Completed	Update	View Details	10/27/2011			
	5 DTSQ		11/03/2011	Completed	Update	View Details	10/27/2011			
	6 SF-8		11/03/2011	Skipped		View Details	10/27/2011			
	7 Demogra	aphic Form	11/01/2011	Completed	Update	View Details	10/27/2011			
	Activity Log									
	Type Dat	te Status		Description			Action			
		7/2011 Enrolled		Step Demographic Form has been completed.						
	System 10/2	7/2011 Enrolled		Step SF-8 has been skipped.						
		7/2011 Enrolled		Step DTSQ has been completed.						
		7/2011 Enrolled		Step Pregnancy Test Negative has been com	pleted					
		7/2011 Enrolled		Step Consent has been completed.						
				Step Visit 1 has been completed.						
	System 10/2	verbally	consented :	step visit i nas been completed.						
e									😝 Internet	🔍 100%

After completing all the Steps in the study, the Complete button will show above the Arm Steps. Click Complete to finish this study. When this study is complete CDMP will allow you to enroll Donald Duck in another study (this enrollment will happen after Donald's provider has been randomized so that Donald can be assigned to a group at that time).

ADDING ANOTHER STUDY (AFTER PROVIDER RANDOMIZATION)

	Subject	Study Details - I	Donald Duck					
nager Lists	5	Study: CADS Patient Pre		Subject Status: Completed	Screener Passed: Yes]	
ct Search	Subject	Arm: All Patients	Signed Info	rmed Consent: Yes tionnaire Code:	Enrollment Date: 10/27.	/2011		
Config ct	Arm St	ens						
	Step #	Step Name	Red Aler	t Status	Action	Finished		
rs	1	Start		Completed	View Details	10/27/2011	1	
	2	Visit 1	11/03/2011	Completed	View Details	10/27/2011		
	3	Consent	11/03/2011	Completed	View Details	10/27/2011		
	4	Pregnancy Test Nega		Completed	View Details	10/27/2011		
	5	DTSQ	11/03/2011	Completed	View Details	10/27/2011		
	6	SF-8 Demographic Form	11/03/2011 11/01/2011	Skipped Completed	View Details View Details	10/27/2011 10/27/2011		
							-	
	Activity Type	y Log Date	Status	Description		Action		
	System	10/27/2011	Completed	The subject has successfully comple	ted this study.	Action		
	System	10/27/2011	Enrolled	Step Demographic Form has been con				
	System	10/27/2011	Enrolled	Step SF-8 has been skipped.			-	
	System	10/27/2011	Enrolled	Step DTSQ has been completed.				
	System	10/27/2011	Enrolled	Step Pregnancy Test Negative has be	en completed			
	System	10/27/2011	Enrolled	Step Consent has been completed.	en eenperen			
	System	10/27/2011	Verbally Consented	Step Visit 1 has been completed.				
	system	10/27/2011	Verbally Consented	The subject has been scheduled for a	inconstruct Visit 1		-	
	Svetem		verbally consented					
	System		Markelly Considered					
	System System System	10/27/2011 10/27/2011	Verbally Consented Eligible	The subject is eligible for the study an The subject passed the screener que			-	

Donald's provider has been randomized, to add him to anther study go to Subject Search.

Comprehensiv Status Center Add			gram		Search User Pref	Admin Help Log C	Dut	^
open all close all	Subject Sea	arch						
Study Manager - To-Do Lists - Subject Search - Create Subject - Study Config	Search Name: Last Name: Minimum Age:	DonaldDuck	Study: First Name: Maximum Age:		Subject Study Status:	v		
⊡-Letters	Phone Number:				importing motion bata.			
				Search Clear				
Done							😜 Internet	€ 100% * .::

Enter the Search Name you created (here it is firstnamelastname)

Comprehensiv Status Center Add			gram		Search User	Pref Admin Help Lo	og Out	^
open all close all	Subject Sea	arch						
Study Manager To-Do Lists Subject Search Create Subject Study Config D-Letters	Search Name: Last Name: Minimum Age: Phone Number:	þonaldDuck	Study: First Name: Maximum Age:	×	Subject Study Status: Importing Medical Data:	v		
	Search Re Last Na + Duck	esults (1 Subjects Fo me First Nam Donald		ch Clear Medical Data No	Research Yes	1 of 1 Add Study		
							😜 Internet	♥ 100% ▼ #

When you get to Donald's record, click on Add Study.

CDMP - Add Study -	Wi 🔳 🗖 🔀
🙋 https://prod.estenda.com/haw	/aii/cads/cdmp 🖌 🔒
Eligible Studies	
CADS Patient Randomized	Add
CADS Provider	Add
	Cancel
	Cancer
For Official Use	Only
😜 Internet	🔍 100% 🔻 🦪

Add Donald to CADS Patient Randomized

Comprehensiv Status Center Add	Ve Diabetes Management Program Search User Pref Admin Help Log Out Patient Studies	^
open all close all	Subject Study Details - Donald Duck	
Study Manager To-Do Lists Subject Search Create Subject	Study: CADS Patient Randomized Study:: New Screener Passed: Not Completed Enrollment Process Information	
-Study Config ⊕-Subject ⊕-Letters	Arm Name*: Group A: Intervention Group 💙 Subject Code: Questionnaire Id:	
	Verbally Consented	
	Type Date Status Description Action System 10/27/2011 New Study added by a user to this subject. Action	
	Add New	
	● Internet %, 100% •	~

Choose the group to which Donald's provider has been assigned (in this example, Group A: Intervention Group). Enter in the subject code and questionnaire id that you have been assigned for this patient and click Verbally Consented.

s Center Add		tes Management Prog Studies					
n all close all	Subjec	t Study Details - Dona	ld Duck				
Manager Do Lists		Study: CADS Patient Randomized	Subje	ect Status: Verbally Consented	Screener Passed: Not Completed		
ect Search		Arm: Group A: Intervention Group	Signed Informed	Consent: No	Enroliment Date:		
te Subject	Culting	Group t Code:	Questionn				
y Config	Subjec	t Code:	questionn	are code:			
ect							
v		_					
ers	Arm S						
ers	Step #		Red Alert	Status	Action Finished		
	1	Start		Completed	Update View Details 10/27/2011		
	2	Confirm Consent	11/01/2011	Active	Complete View Details		
	3	Visit 2	11/01/2011	Not Scheduled	Schedule View Details		
	4	iMetrikus		Inactive			
	5	Visit 2 Form		Inactive			
	6	iMetrikus		Inactive			
	8	iMetrikus		Inactive Not Scheduled	Schedule		
	9	Visit 3 Visit 3 Form		Inactive	Schedule		
	10	iMetrikus		Inactive			
	11	iMetrikus		Inactive			
	12	iMetrikus		Inactive		_	
	12	Visit 4		Not Scheduled	Schedule		
	14	iMetrikus		Inactive	Schedule		
	15	Visit 4 Form		Inactive		-	
	16	iMetrikus		Inactive			
	17	iMetrikus		Inactive			
	18	Visit 5		Not Scheduled	Schedule		
	19	iMetrikus		Inactive			
	20	Visit 5 Form		Inactive			
	21	iMetrikus		Inactive			
	22	iMetrikus		Inactive			
	23	Visit 6		Not Scheduled	Schedule		
						-	

You will now repeat the process as you did for the previous study by scheduling appointments according to the Study Protocol and completing steps as they arise in your reminders and alerts.

SEARCHING FOR A SPECIFIC SUBJECT

Done

Comprehensiv	/e Diabetes Managemer	nt Program			Search User Pref	Admin Help	Log Out	^
open all close all	Patient Studies							
Study Manager	Study Manager Home							
-To-Do Lists - <u>Subject Search</u>								
-Create Subject	Studies				Status: All	*		
-Study Config ⊡-Letters	Study Name CADS Provider	Planned Start 07/01/2011	Planned End 10/18/2012	Enrollment 2 of 12 enrolled	Search Search Subjects			
	CADS Patient Pre-provider Randomization	10/18/2011	10/18/2012	9 of 228 enrolled	Search Subjects			
	CADS Patient Randomized	10/18/2011	10/18/2012	0 of 228 enrolled	Search Subjects			
								 ~
https://prod.estenda.c	om/hawaii/cads/cdmp/subjects	Search.do?task=new					😜 Internet	 100% 🔹 🦽
Comprehensiv	ve Diabetes Managemei	nt Program			Search User Pref	Admin Help	Log Out	^
Status Center Add	Patient Studies							
open all close all	Subject Search							
Study Manager								
To-Do Lists	Search Name: DonaldDuck	Study		*	Subject Study Status:	*		
-Subject Search Create Subject	Last Name:	First Name						
-Study Config	Minimum Age:	Maximum Age			Importing Medical Data:	*		
⊡-Letters	Phone Number:							
			Search	Clear				

😜 Internet

at 100% 🔹

Comprehensiv	/e Diabetes Management Progran Patient Studies	1		Search User Pre	f Admin	Help Log Out)	~
open all close all	Subject Search							
Study Manager	Saarah Nama, DagakiDuak	Shuduu		Subject Study Status		*		
—To-Do Lists —Subject Search	Search Name: DonaldDuck Last Name:	Study: irst Name:	~	Subject Study Status:		×		
-Create Subject Study Config		imum Age:		Importing Medical Data:	~			
⊞-Letters	Phone Number:	inum Age.		importing medical Data.	Ť			
		Search	Clear					
		Search	Clear				_	
	Search Results (1 Subjects Found) Last Name First Name	Date of Birth	Medical Dat	ta Research	1 of 1	1		
	+ Duck Donald	05/15/1942	No No	Yes	Add Study			
Done							😜 Internet	€ 100% · .;;
								4100 //
	s://prod.estenda.com/hawaii/cads/cdmp/sul	iest leure de				v 🔒 🐓	× ako	
		Jecthome.do				•		
	avorites Tools Help		Y)				»
	Smail - Inbox - sarasalk 🌈 CDMP - Subje		wledge Online					🔹 🔹 🔂 Page 🔻 🍈 Tools 👻 🦉
Status Center Add	ve Diabetes Management Progran Patient Studies	1		Search User Pre	f Admin	Help Log Out)	<u>^</u>
open all close all	Subject Home - Donald Duck	√ Research						
Study Manager — To-Do Lists	Studies Targeted/Enrolled				Add Stud	v		
-Subject Search	Study Study Status	Subject Status	Arm	Enroll. Date				
-Create Subject Study Config	provider Randomization In Progress	Enrolled	All Patients	10/27/2011	Add Note			
⊕-Subject			Timeframe:		Study	<u>c</u>		
⊞-Letters	Appointments		Al 🗸		~			
	Date & Time Notes		Provider	Study Name CADS Patient Pre-				
	10/29/2011 08:00 AM		Laurie	provider Randomization				
				K				
				•				
Done	•						😜 Internet	€ 100% · .::

sen all j close all Subject Study: CADS Patient Pre- provier Randomization Subject Status: Enrolled Screener Passed: Yes biget Stach, in provier Randomization Signed Informad Consent: Yes Enrollment Date: 10/27/2011 biget Stach, in provier Randomization Signed Informad Consent: Yes Enrollment Date: 10/27/2011 biget Stach, in provier Randomization Signed Informad Consent: Yes Enrollment Date: 10/27/2011 biget Stach, in provier Randomization Signed Informad Consent: Yes Enrollment Date: 10/27/2011 biget Stach, in provier Randomization Signed Informad Consent: Yes Enrollment Date: 10/27/2011 biget Stach, in provier Randomization Signed Informad Consent: Yes Enrollment Date: 10/27/2011 biget Stach, in provier Randomization Signed Informad Consent: Yes Enrollment Date: 10/27/2011 biget Stach, in provier Randomization Signed Informad Consent: Yes Enrollment Date: 10/27/2011 biget Stach, in provier Randomization Signed Information Completed Update View Details 10/27/2011 consent: Yes Signed Information Completed Update View Details 10/27/2011 consent: Yes Signed Information Completed Update View Details 10/27/2011 consent: Yes		d Patient Stu	es Management F Idies	rogram		Search User Pre			
Study: Study: Study: Study: Study: Study: Study: Appendix Search reales Subject (abject Search reales Subject Code: Signed Informat Consent: Yes Enrollment Date: 10/27/2011 Stop & Step Name Red Alert Status Action Finished 1 Stat Completed Update View Details 10/27/2011 2 Visit 11/03/2011 Completed Update View Details 10/27/2011 3 Consent 11/03/2011 Completed Update View Details 10/27/2011 4 Prepnany Test Negative 11/03/2011 Completed Update View Details 10/27/2011 5 DTSQ 11/03/2011 Completed Update View Details 10/27/2011 5 DTSQ 11/03/2011 Active Completed Update View Details 6 SF-8 11/03/2011 Active Completed Update View Details 7 Demographic Form 11/03/2011 Active Completed Update View Details 8 System 10/27/2011 Enrolled Step Pregnancy Test Negative has been completed. System 9 System 10/27/2011 Enrolled Step Pregnancy Test Negative has been completed. Sy	en all close all	Subject :	Study Details - D	onald Duck					
Study: Study: Study: Study: Study: Study: Study: Study: Status: Enrolled Screener Passed: Yes ubject Search reate Subject Stop & Step Name All Patients Signed Informad Consent: Yes Enrollment Date: 10/27/2011 ubject Code: Arm Steps Completed Update View Details 10/27/2011 2 Vist 1 11/03/2011 Completed Update Update 10/27/2011 3 Consent 11/03/2011 Completed Update Update 10/27/2011 3 Consent 11/03/2011 Completed Update Update 10/27/2011 4 Prepnancy Test Negative 11/03/2011 Completed Update View Details 10/27/2011 5 DTSQ 11/03/2011 Completed Update View Details 10/27/2011 5 DTSQ 11/03/2011 Active Completed Update View Details 6 SF-3 11/03/2011 Active Completed View Details 7 Demographic Form 11/03/2011 Active Completed View Details 8 System 10/27/2011 Enrolled Step Consent has								_	
Subject Search Arm: All Patients Signed Inform d Consent: Yes Enrollment Date: 10/27/2011 Subject Code: Cuestionnaire Code: Cuestionnaire Code: Subject Code: Cuestionnaire Code: Cuestionnaire Code: Subject Code: Cuestionnaire Code: Cuestionnaire Code: Subject Code: Cuestionnaire Code: Finished Step # Step Name Red Alert Status Arm Steps Step # Step Name Completed 1 Start Completed Update View Details 2 Visit 1 11/03/2011 Completed Update 4 Pregnancy Test Negative 11/03/2011 Completed Update 5 DTSQ 11/03/2011 Active Completed 7 Demographic Form 11/03/2011 Active Complete 7 Demographic Form 11/01/2011 Active Complete System 10/27/2011 Enrolled Step Consent Als been completed. S		s			Subject Status: Enrolled	Screener Passed: Yes			
Subject Code: Questionmaire Code: Subject Code: Questionmaire Code: Mark Steps Stop & Step Name Red Alert Status Action Finished 1 Start Completed Update View Details 1027/2011 2 Vist 1 11/03/2011 Completed Update View Details 1027/2011 3 Consent 11/03/2011 Completed Update View Details 1027/2011 4 Pregnancy Test Negative 11/03/2011 Completed Update View Details 1027/2011 5 DTSQ 11/03/2011 Completed Update View Details 1027/2011 5 DTSQ 11/03/2011 Active Completed View Details 1027/2011 7 Demographic Form 11/03/2011 Active Completed View Details			 provider Randomia 				011		
State Subject Arm Steps vdy Config Start Complete vdy Start Completed 12 Vat 1 1103/2011 2 Vat 1 1103/2011 3 Consent 1103/2011 4 Pregnancy Test Negative 1103/2011 5 DTSQ 1103/2011 6 SF-8 1103/2011 7 Demographic Form 11/03/2011 7 Demographic Form 11/03/2011 8 SF-8 11/03/2011 7 Demographic Form 11/03/2011 4 Active Complete 7 Demographic Form 11/03/2011 8 SF-8 11/03/2011 9 Verable Step Pregnancy Test Negative has been completed. 9 View Details 10/27/2011 8 Step Pregnancy Test Negative has been completed. System 9 Verbally Consented Step Pregnancy Test Negative has been completed. 9 System 10/27/2011 Enroled 9 System 10/27/2011 Enroled 9 Verbally Consented The subject has been achelided for appointment Vist 1. 9 System 10/27/2011						Enroliment bate: 10/2//2	011		
Arm Steps dy ters Arm Steps Arm Steps Arm Steps Arm Steps Arm Steps Step # Step Name Red Alert Complete Update Usev Details 1027/2011 2 Vari 1 103/2011 Complete Update Usev Details 1027/2011 3 Consent 11/03/2011 Complete Update Usev Details 1027/2011 5 OTSQ 11/03/2011 Complete Update Usev Details 1027/2011 5 OTSQ 11/03/2011 Complete Usev Details 1027/2011 5 OTSQ 11/03/2011 Active Complete View Details 1027/2011 Complete View Details 1027/2011 Active Complete View Details 1027/2011 Complete View Details Complete View Details 1027/2011 Complete View Details Complete									
Arm Steps Step # Step # Step # 1 Start Completed Update View Details 10/27/2011 2 Visit 1 11/03/2011 Completed Update View Details 10/27/2011 3 Consent 11/03/2011 Completed Update View Details 10/27/2011 4 Pregnancy Test Negative 11/03/2011 Completed Update View Details 10/27/2011 5 DTS0 11/03/2011 Completed Update View Details 10/27/2011 5 DTS0 11/03/2011 Active Complete View Details 10/27/2011 7 Demographic Form 11/03/2011 Active Complete View Details 10/27/2011 8ystem 10/27/2011 Enrolled Step Pregnancy Test Negative has been completed. System 10/27/2011 Enrolled System 10/27/2011 Enrolled Step Consent has been completed. System System 10/27/2011 Verbally Consented The subject has been completed. System 10/27/2011 Verbally Consented The subject has been completed. System System 10/27/2011 Verbally Consented Step Consent has been completed. System 10/27/2011 Verbally Consented									
Joby Step # Step Name Red Alert Status Action Finished 1 Start Completed Update View Details 100270011 2 Visit 1 11/032011 Completed Update View Details 100270011 3 Consent 11/032011 Completed Update View Details 1027/2011 4 Pregnancy Test Negative 11/032011 Completed Update View Details 1027/2011 5 DTSQ 11/032011 Complete View Details 1027/2011 6 SF-8 11/032011 Active Complete View Details 7 Demographic Form 11/012011 Active Complete View Details 7 Demographic Form 11/012011 Active Complete View Details 7 Demographic Form 11/012011 Active Complete View Details 9 10/27/2011 Enroled Step Pregnancy Test Negative has been completed. System 9 10/27/2011 Enroled Step Visit 1 has been completed. System <td></td> <td>Arm Ste</td> <td>eps</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		Arm Ste	eps						
2 Visit 1 11/03/2011 Completed Update View Details 10/27/2011 3 Consent 11/03/2011 Completed Update View Details 10/27/2011 4 Pregnancy Test Kegative 11/03/2011 Completed Update View Details 10/27/2011 5 DTSQ 11/03/2011 In Progress Complete View Details 6 SF-8 11/03/2011 Active Complete View Details 7 Demographic Form 11/01/2011 Active Complete View Details 9 System 10/27/2011 Enrolled Step Pregnancy Test Negative has been completed. System System 10/27/2011 Enrolled Step Oreanth as been completed. System Step Virally Consented The subject has been achilded for appointment Vist 1. System System 10/27/2011 Verbaily Consented The subject has scene achilded for pointment Vist 1. System 10/27/2011 Verbaily Consented The subject has scene activationnale. System 10/27/2011 Verbaily Consented The s			Step Name	Red Aler					
3 Consent 1103/2011 Completed Update View Details 10/27/2011 4 Pregnancy Test Negative 1103/2011 Completed Update View Details 10/27/2011 5 DTSQ 1103/2011 Active Complete View Details 10/27/2011 6 SF-8 11/03/2011 Active Complete View Details View Details 7 Demographic Form 11/03/2011 Active Complete View Details Activity Log System 10/27/2011 Enrolled Step Pregnancy Test Negative has been completed. System 10/27/2011 Enrolled Step Consent thas been completed. System 9ystem 10/27/2011 Enrolled Step Consent thas been completed. System 9ystem 10/27/2011 Verbaily Consented Step Consent thas been completed. System 9ystem 10/27/2011 Verbaily Consented The subject as been acchevide for appointment Vist 1. System System 10/27/2011 Verbaily Consented The subject as series or great on plant werbaily agreed to join the study. System 10/27/2011 Verbaily Consented The subject assest the screener questionnaire. System System 10/27/2011 New St	tters	1	Start		Completed				
4 Preparancy Test Negative 11/03/2011 Completed User Details 10/07/2011 5 DTSQ 11/03/2011 In Progress Complete View Details 10/07/2011 6 SF-3 11/03/2011 Active Complete View Details 7 Demographic Form 11/01/2011 Active Complete View Details Activity Log Activity Log System 10/07/2011 Enrolled Step Pregnancy Test Negative has been completed. System 10/07/2011 Enrolled Step Oregnancy Test Negative has been completed. System 10/07/2011 Verbally Consented The subpct has been completed. System 10/07/2011 Verbally Consented The subpct has been completed. System 10/07/2011 Verbally Consented The subpct has been completed. System 10/07/2011 Verbally Consented The subpct has been completed. System 10/07/2011 Verbally Consented The subpct has been completed. System 10/07/2011 Verbally Consented The subpct has been completed. System 10/07/2011 Verbally Consented The subpct has been completed. System 10/07/2011 Verbally Consented The subpct									
S DTSQ 11/03/2011 In Progress Complete View Details 6 SF-8 11/03/2011 Active Complete View Details 7 Demographic Form 11/01/2011 Active Complete View Details Activity Log Activity Log Type Date Status Description Action System 10/27/2011 Enrolled Step Pregnancy Test Negative has been completed. System 10/27/2011 Enrolled Step Visit 1 has been completed. System 10/27/2011 Verbaily Consented The subject has been achediated for appointment Visit 1. System 10/27/2011 Verbaily Consented The subject has been achediated for appointment Visit 1. System 10/27/2011 Verbaily Consented The subject has been achediated for appointment Visit 1. System 10/27/2011 Verbaily Consented The subject has been achediated by an verbaily agreed to join the study. System 10/27/2011 Elipible The subject has been achediated by an verbaily agreed to join the study. System 10/27/2011 New Study added by a user to this subject.		-							
6 SF-8 11/03/2011 Active Complete View Details 7 Demographic Form 11/01/2011 Active Complete View Details Activity Log Activity Log System 10/27/2011 Enrolled Step Pregnancy Test Negative has been completed. System 10/27/2011 Enrolled Step Onsent has been completed. System 10/27/2011 Verbaily Consented The subject has been completed. System 10/27/2011 Verbaily Consented The subject has been completed. System 10/27/2011 Verbaily Consented The subject has been scheduled for appointment Visit 1. System 10/27/2011 Verbaily Consented The subject is eligible for the study, and verbaily agreed to join the study. System 10/27/2011 Eligible The subject as the screener questionnaire. System 10/27/2011 New Study added by a user to this subject.									
7 Demographic Form 11/01/2011 Active Complete View Details Activity Log Type Date Status Description Action System 10/27/2011 Enrolled Step Pregnancy Test Negative has been completed. System System 10/27/2011 Enrolled Step Visit I has been completed. System System 10/27/2011 Verbaily Consented The subject has been acheduled for appointment Visit 1. System System 10/27/2011 Verbaily Consented The subject has been acheduled for appointment Visit 1. System System 10/27/2011 Verbaily Consented The subject has been acheduled for appointment Visit 1. System System 10/27/2011 Eligible The subject has been the screener questionnaire. System System 10/27/2011 New Study added by a user to this subject. Study added by a user to this subject.									
Activity Log Date Status Description Action System 10/27/2011 Enrolled Step Pregnancy Test Negative has been completed. System 10/27/2011 Enrolled Step Consent has been completed. System 10/27/2011 Verhally Consented Step Vise1 has been completed. System 10/27/2011 Verhally Consented The subject has been scheduled for appointment Vist 1. System 10/27/2011 Verhally Consented The subject is eligible for the study and verhally agreed to join the study. System 10/27/2011 Eligible The subject as the scheence usetionnaire. System 10/27/2011 Eligible The subject as the scheence usetionnaire. System 10/27/2011 Eligible The subject as the scheence usetionnaire. System 10/27/2011 Eligible The subject asset of the scheence usetionnaire. System 10/27/2011 New Study added by a user to this subject. Study added by a user to this subject.		7							
System 10/27/2011 Enrolled Step Pregnancy Test Negative has been completed. System 10/27/2011 Enrolled Step Onsent has been completed. System 10/27/2011 Verbally Consented Step Onsent completed. System 10/27/2011 Verbally Consented The subject has been scheduled for appointment Visit 1. System 10/27/2011 Verbally Consented The subject is eligible for the study and verbally agreed to join the study. System 10/27/2011 Eligible The subject as been encompleted. System 10/27/2011 Verbally Consented The subject as the screener questionnaire. System 10/27/2011 Eligible The subject as the screener questionnaire. System 10/27/2011 New Study added by a user to this subject.									
System 10/27/2011 Enrolled Step Consent has been completed. System 10/27/2011 Verbaily Consented These uncompleted. System 10/27/2011 Verbaily Consented The subject has been acheduled for appointment Vist 1. System 10/27/2011 Verbaily Consented The subject has been acheduled for appointment Vist 1. System 10/27/2011 Verbaily Consented The subject has been acheduled for appointment Vist 1. System 10/27/2011 Eligible The subject has been acheduled for appointment. System 10/27/2011 Eligible The subject has been acheduled for appointment. System 10/27/2011 Kudy added by a user to this subject.				Statuc	Description		Action		
System 10/27/2011 Verbally Consented Step Visit 1 has been completed. System 10/27/2011 Verbally Consented The subject has been acheduled for appointment Visit 1. System 10/27/2011 Verbally Consented The subject is eligible for the study and verbally agreed to join the study. System 10/27/2011 Eligible The subject ased the screener questionnaire. System 10/27/2011 New Study added by a user to this subject.		Туре	Date			een completed	Action		
System 10/27/2011 Verbally Consented The subject is eligible for the study and verbally agreed to join the study. System 10/27/2011 Eligible The subject passed the screener questionnaire. System 10/27/2011 New Study added by a user to this subject.		Type System	Date 10/27/2011	Enrolled	Step Pregnancy Test Negative has b	een completed.	Action		
System 10/27/2011 Eligible The subject passed the screener questionnaire. System 10/27/2011 New Study added by a user to this subject.		Type System System	Date 10/27/2011 10/27/2011	Enrolled Enrolled	Step Pregnancy Test Negative has b Step Consent has been completed.	een completed.	Action		
System 10/27/2011 New Study added by a user to this subject.		Type System System System	Date 10/27/2011 10/27/2011 10/27/2011	Enrolled Enrolled Verbally Consented	Step Pregnancy Test Negative has b Step Consent has been completed. Step Visit 1 has been completed.		Action		
		Type System System System System	Date 10/27/2011 10/27/2011 10/27/2011 10/27/2011	Enrolled Enrolled Verbally Consented Verbally Consented	Step Pregnancy Test Negative has b Step Consent has been completed. Step Visit 1 has been completed. The subject has been scheduled for	appointment Visit 1.	Action		
Add Nov		Type System System System System	Date 10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011	Enrolled Enrolled Verbally Consented Verbally Consented Verbally Consented	Step Pregnancy Test Negative has b Step Consent has been completed. Step Visit 1 has been completed. The subject has been scheduled for The subject is eligible for the study a	appointment Visit 1. nd verbally agreed to join the study.	Action		
		Type System System System System System	Date 10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011	Enrolled Enrolled Verbally Consented Verbally Consented Verbally Consented Eligible	Step Pregnancy Test Negative has b Step Consent has been completed. Step Visit 1 has been completed. The subject has been scheduled for The subject is eligible for the study a The subject passed the screener qui	appointment Visit 1. nd verbally agreed to join the study. estionnaire.	Action		
		Type System System System System System	Date 10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011	Enrolled Enrolled Verbally Consented Verbally Consented Verbally Consented Eligible	Step Pregnancy Test Negative has b Step Consent has been completed. Step Visit 1 has been completed. The subject has been scheduled for The subject is eligible for the study a The subject passed the screener qui	appointment Visit 1. nd verbally agreed to join the study. estionnaire. t.	Action Add New		
		Type System System System System System	Date 10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011	Enrolled Enrolled Verbally Consented Verbally Consented Verbally Consented Eligible	Step Pregnancy Test Negative has b Step Consent has been completed. Step Visit 1 has been completed. The subject has been scheduled for The subject is eligible for the study a The subject passed the screener qui	appointment Visit 1. nd verbally agreed to join the study. Estionnaire. t.			
		Type System System System System System	Date 10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011	Enrolled Enrolled Verbally Consented Verbally Consented Verbally Consented Eligible	Step Pregnancy Test Negative has b Step Consent has been completed. Step Visit 1 has been completed. The subject has been scheduled for The subject is eligible for the study a The subject passed the screener qui	appointment Visit 1. nd verbally agreed to join the study. Estionnaire. t.			
		Type System System System System System	Date 10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011 10/27/2011	Enrolled Enrolled Verbally Consented Verbally Consented Verbally Consented Eligible	Step Pregnancy Test Negative has b Step Consent has been completed. Step Visit 1 has been completed. The subject has been scheduled for The subject is eligible for the study a The subject passed the screener qui	appointment Visit 1. nd verbally agreed to join the study. Estionnaire. t.			

Appendix C Suggested Questions for CADS Focus Groups

- 1. Topics for discussion:
- 2. Have you used the system (how much)?
- 3. Do you like the system (likert scale 1 to 5)
- 4. Have you encountered problems? If yes, what kind (more serious first)
- 5. Access
- 6. Understanding of outputs (which outputs)
- 7. Disagree with recommendations? Why
- 8. Utility of other features:
 - a. Retrieval of laboratory data: A1C Creatinine BUN
 - b. Retrieval of SMBG data
 - c. Glucose statistics
 - d. Glucose graphs
 - 1. By date
 - 2. By time of day
 - 3. Pie charts
 - 4. Stacked bar charts
 - 1. Which do you prefer pie charts or stacked bar charts?
 - e. Glucose Logbooks
 - f. Display of current medications
 - g. Medication history
 - h. Data entry side effects and contraindications
 - 1. Gi-, Renal-, hepatic-, cardiac-, other- side effects
- 9. How much time does it take to use the system for a typical patient visit?
- 10. How much time does it take to review the output for a typical patient visit, if using the system in that manner?
- 11. Which mode of operation would you prefer using system online or viewing the output that has been emailed to you immediately before the patient visit?
- 12. Why?
- 13. Pros and cons of each (if having had chance to use both)?
- 14. What additional features would you like to see entered into the CADS system?
- 15. Is it comfortable to use the CADS system?
- 16. Would you recommend it to others?
- 17. Would you recommend it to the following types of potential users:
- 18. Physicians in general

- 19. NPs in general
- 20. PAs in general
- 21. Primary care physicians
 - a. Internists
 - b. Pediatricians
 - c. OB/GYN
 - d. Family Practitioners
- 22. NPs
- 23. PAs
- 24. Pharmacists
- 25. Diabetes Educators
- 26. Was the CADS system reasonably consistent (look and feel and mode of operation) with CDMP? With CIU? With AHLTA? With other systems with which you may be familiar? (specify system(s):
 - a. _____
 - b. _____
 - C. _____

27. What did you like best about the CADS system?

- 28. What did you like least about the CADS system?
- 29. Is there anything that needs to be changed immediately with the system?
- 30. Open discussion: Topics the (focus group participants) would like to bring up?
- 31. Wrap-up:
- 32. Ask the participants to select a spokesperson to provide a wrap up or overview.

Appendix D Suggested Questions for Usual Care Focus Groups

- 1. How do they like CDMP?
- 2. How do they like AHLTA
- 3. How frequently do they think that patients with T2DM should be testing SMBG
- 4. How many times per day
- 5. Do they like the idea of structured testing, e.g. 7 times per day, 3 days per week? Have they used that? Does that improve care and outcomes?
- 6. How do they analyze the patient data? Logbooks, computer printouts?
- 7. What graphs do they use and like? What percent of time do they have access to that?
- 8. If they had access to graphs and statistics, which ones would they want?
- 9. Would they want access to formulary? Prescribing information? Guidelines,? Medical literature? Instructions to patients? Other?
- 10. How much time do they spend with a typical patients?
- 11. How much time do they think they should spend with each patient, on average?
- 12. What tools or computer systems do they think they would like?
- 13. What percentage of clinic visits do you make a change in therapy?
- 14. What percentage of the changes in therapy that you make, are followed by an improvement within 3 months? Within 6 months?
- 15. How confident are you, that you can adjust therapy for patients with diabetes, in accord with the standard of practice in the community? In accord with the best practices?
- 16. Where can one find the "best practices"? specify
 - a. Are you aware of available guidelines or algorithms?
 - a. If yes, where?
 - 1. ADA: guidelines or algorithms
 - 2. AACE: guidelines or algorithms
 - 3. DOD/VA: guidelines or algorithms
 - 4. Other: guidelines or algorithms
 - 1. Inzucchi diabetes fact book
 - 2. Canadian
 - 3. Italian
 - 4. Brazilian
 - 5. other(?)
- 17. If the computer would make recommendations, what percentage of the time are you (they) likely to follow those recommendations?
- 18. What are the factors that would influence how you would respond to the recommendations?
 - a. Who developed the system?

- b. What the logic was based on?
- c. Ease and speed of use?
- d. Concern that this system might distract you from the patient and the doctor-patient relationship?
- e. Concern that the patient might not accept the idea that you are using that system
- f. If you had access to a clinical decision support systm, what would you want it to do?
- g. Would you want it to provide a recommendation for a best course of action (e.g. change medication regimen, add insulin, etc.) or would you want to have it present a series of plausible alternatives?
- 19. How important would it be for the computer to provide an explanation of the recommendations that it is making?
- 20. Where do you normally go for advice, when you encounter a patient with a complex case, if you do not feel 95%+ confident that you can handle the case adequately by yourself?
 - a. Fellow
 - b. Resident
 - c. Attending
 - d. Endocrinology consult
 - e. Library
 - f. Online textbooks or reference sources
 - g. Pubmed
 - h. ePocrates
 - i. PDR or equivalent

What are the biggest problems that you face when handling patients with type 2 diabetes?

Which - if any of those problems, do you think could be handled by a "clinical decision support" system?

What should such a system do?

How would you access it? Online, at time of visit? Online before the visit? Via email?

How often do you change therapy in your patients?

Every visit?

Every other visit

Every third visit, on average?

About once per year

Less often

In between office visits by email or telephone

How often do you think clinicians should change therapy

What is the A1C level that you regard as an appropriate target for most patients? How is that arrived at?

What factors should one consider when arriving at a target level of A1C?

(first do open ended)

Age of patient

Life expectancy

- Duration of diabetes?
- Presence of known complications?
- History of hypoglycemia episodes? Frequency? Severity?
- Hypoglycemia unawareness
- Occupation
- Other medications
- Other topics chosen by group
- Wrap-up by spokesman for the group
- Wrap-up by session moderator